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ABSTRACT 
The NF-!B family of transcription factors are essential for different stages of murine 
haemopoiesis as supported by studies on single or double knockout mice.  The function of 
NF-!B1 and NF-!B2 in haemopoietic stem cells (HSCs) has never been described before.  
In mice, the bone marrow c-Kit+Sca1+Lin- (KSL) population represent HSCs that have the 
ability to repopulate the bone marrow of lethally irradiated animals.  Using knockout mice 
technology we were able to study the function of NF-!B1 and NF-!B2 in HSCs by 
performing amongst others transplantation assays, which is the most precise way to test 
HSC potential.  Nf!b1-/- KSL cells are fully able to reconstitute lethally irradiated 
recipients indicating that the in vivo self-renewal capacity is unaffected. In contrast, colony 
assays showed NF-!B1 dependency.  Upon serial replating, knockout cells were not able 
to form colonies and lost their in vitro self-renewal capacity. Transplantation of the nf!b2-/- 
KSL cells engraft with a proliferative phenotype and a competitive advantage, with 
changes in the B-cell and myeloid cell lineages.  Similar to nf!b1-/-, nf!b2-/- KSL cells lose 
their function as stem cells upon serial replating.  These findings highlight the importance 
of NF-!B family proteins in HSCs, especially NF-!B2 and should be considered in the 
development of future cancer treatment that target NF-!B proteins. 
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CHAPTER 1 
INTRODUCTION 
1.1 Stem cells 
In the 19th century the term ‘stem cell’ was used to describe germ line cells that give rise to 
eggs and sperms.  However, more recently stem cells have been defined as unspecialized cells 
that give rise to differentiated cells.  In 1961 Till and McCulloch demonstrated that colonies 
of myeloid cells developing in the spleen were clonal following transplantation of bone 
marrow into lethally irradiated mice (Till and McCulloch, 1961). 
Stem cells play an important role for the life of multi-cellular organisms as they are required 
during the development of the embryo and also throughout life for the maintenance of tissues 
and organs.  Stem cells have two defining properties that distinguish them from other cells: 
the ability to differentiate into one or more cell types and a capacity to self-renew (i.e. to 
divide and produce another of itself so that it does not become depleted).  The stem cell 
potency depends on the developmental stage, and is operationally defined by the number of 
distinct cell lineages they are able to give rise to.  Totipotent stem cells are cells that after 
fertilization give rise to both the complete embryo and the extraembryonic tissues such as the 
placenta.  Pluripotency is seen in embryonic stem cells (ESCs), which have an unlimited 
capacity for growth and can differentiate into all embryonic cell types.  Adult stem cells have 
a more restricted potency and are associated with providing cells for tissues and organs they 
are part of.  These cells are also referred to as tissue or somatic stem cells and may be 
multipotent (e.g. bone marrow derived stem cells that give rise to all cellular components of 
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the blood) or monopotent (such as those found in skeletal muscle which give rise to a single 
lineage). 
A different category of stem cells can be created by so called ‘reprogramming’.  In this 
process the gene expression pattern of differentiated cells of the adult body, such as skin 
fibroblasts, is changed artificially to recapitulate the earliest stage of development.  In this 
way the reprogrammed stem cells acquire a pluripotency property like ESCs.  There are 
different ways to achieve reprogramming, however the two essential approaches are ‘nuclear 
transfer’ and the generation of ‘induced pluripotent stem’ cells (iPS cells).   
Nuclear transfer was achieved 50 years ago by John Gurdon, who inserted the nucleus of a 
differentiated skin cell into an enucleated egg and generated cloned frogs (Gurdon et al., 
1958).  This strategy was also used later when Dolly the sheep was cloned from the nucleus of 
a mammary gland epithelial cell (Campbell et al., 1996).  In the cloning process there are 
proteins and probably other molecules in the cytoplasm of the oocyte that reset the 
developmental clock and thus revert the gene expression profile.   
The second approach of reprogramming was achieved by Takahashi and Yamanaka in 2006, 
when they showed that expression of four transcription factors in differentiated murine 
somatic cells induced iPS cells with a pluripotency phenotype that is very similar to that of 
ESCs (Takahashi and Yamanaka, 2006).  One year later iPS cells were also generated from 
adult human fibroblasts (Takahashi et al., 2007).  The use of iPS cells solves many practical 
and ethical problems that apply to ESCs, as these are patient-specific, do not involve 
destruction of an embryo and are able to provide an unlimited supply of stem cells.  However 
these cells have still some potential problems as they tend to keep some of the epigenetic 
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profiles of the adult cells from which they were derived, and this might affect the 
differentiation properties of the iPS cells with time. 
 
1.2 The haemopoietic hierarchy 
Haemopoiesis is defined as the cellular process by which the eight major lineages of blood 
cells are generated.  These cells mature to functionally active cells and are often short-lived.  
Thus, haemopoiesis continues actively throughout the life of an individual.  The haemopoietic 
system can be sub-divided into three compartments.  The first compartment contains 
haemopoietic stem cells (HSCs), including long-term (LT) HSCs, which are able to self-
renew for an unlimited time period, and short-term (ST) HSCs, which self-renew for a limited 
time period (Passegue et al., 2003).  These later cells, known as ‘KSL’ cells in the mouse, are 
positive for the stem cell surface markers c-Kit (the receptor for stem cell factor, SCF) and 
Sca-1 (Okada et al., 1992), and negative for lineage markers which usually include B220, 
CD5, CD8, Gr1, CD11b (Mac-1) and Ter119.  The ST-HSCs differentiate into multipotent 
progenitors (MPPs), which in turn differentiate into two lineage-restricted progenitors, 
common lymphoid progenitors (CLP) and common myeloid progenitors (CMP).  CLP give 
rise to T-lymphocytes, B-lymphocytes and natural killer (NK) cells while CMPs differentiate 
first into myelomonocytic (granulocyte/macrophage) progenitors (GMPs) and 
megakaryocyte/erythroid progenitors (MEPs).  GMPs differentiate then into 
monocytes/macrophages and granulocytes whilst MEPs produce megakaryocytes/platelets 
and erythrocytes.  CMPs as well as CLPs produce dendritic cells (Figure 1.1) (Passegue et al., 
2003, Bonnet and Dick, 1997).  
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Figure 1.1: Schematic of the haemopoietic hierarchy.  Model of the haemopoietic 
developmental hierarchy consisting of (i) Stem cells and multipotent progenitors: 
long-term haemopoietic stem cells (LT-HSC), short-term haemopoietic stem cells 
(ST-HSC), multipotent progenitor (MPP); (ii) Committed proliferating progenitors: 
common myeloid progenitor (CMP), common lymphoid progenitor (CLP), 
megakaryocyte / erythroid progenitor (MEP), granulocyte / macrophage progenitor 
(GMP); and (iii) Mature differentiated cells: erythrocyte, platelets, granulocytes, 
macrophages, dendritic cells, B- cells, natural killer cells (NK-cells) and T-cells. 
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1.3 Development of the haemopoietic system 
Several anatomical parts of the foetus participate in foetal haemopoiesis.  The location of 
haemopoiesis changes from one site to another as the embryo grows and its anatomy changes 
during organogenesis.  In mice the earliest blood cells arise between embryonic day 7 and 8 
(E7-E8) in the yolk sac (Moore and Metcalf, 1970, Haar and Ackerman, 1971).  These cells 
are nucleated primitive erythroblasts that synthesise haemoglobin and enter the embryo when 
the circulation is established.  At around E12 to E13 the foetal liver becomes the predominant 
haemopoietic organ where definitive haemopoiesis takes place and non-nucleated 
erythroblasts are formed (Barker, 1968).  The liver displays continuous haemopoietic activity 
throughout development in utero and also several weeks postnatally (Wolf et al., 1995, 
Harrison et al., 1979, Kurata et al., 1998).  By E16 to E18 the murine bone marrow 
compartments are the main and final sites in which haemopoiesis is initiated (Velardi and 
Cooper, 1984).  Both the spleen and the bone marrow function as the primary organs of blood 
cell production throughout the life of the mouse.   
 
1.4 Haemopoietic stem cell identification, isolation and characterisation 
Different techniques have been developed to identify and isolate HSCs, which include 
enrichment (magnetic cell separation- MACS), single cell sorting (fluorescence-activated cell 
sorting-FACS) based on cell surface markers and vital dye staining (Challen et al., 2009).   
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1.4.1 Haemopoietic stem cell isolation using cell surface antigens  
There is no single marker that separates HSCs from other haemopoietic cells.  However, 
different antibody combinations have been established to purify these cells using 
multiparameter flow cytometry.  Murine HSCs are a population of cells that phenotypically 
do not express surface markers characteristic of differentiated haemopoietic cells (Muller-
Sieburg et al., 1986), which include CD5, B220, CD4, CD8, Gr1, CD11b (Mac-1) and 
Ter119, while they display high levels of Sca1 (Spangrude et al., 1988) and receptor tyrosine 
kinase c-Kit (Okada et al., 1992).  Thus, these cells are c-Kit+Sca1+Lin-, known as KSL-cells.  
However the KSL compartment is heterogeneous, containing a mixture of LT-HSCs, ST-
HSCs and MPPs.   
With the markers CD34 and Flt3 (also known as Flk-2or CD135) it is possible to further 
divide the KSL population into more homogeneous populations.  LT-HSCs are the true 
transplantable HSCs and are negative for CD34 (KSL CD34-) (Osawa et al., 1996).  Addition 
of the Flt3 marker makes it possible to not only define the LT-HSC (KSL CD34- Flt3-) but 
also the ST-HSC population (KSL CD34+ Flt3-) and MPP population (KSL CD34+ Flt3+) 
within the KSL cells (Christensen and Weissman, 2001, Adolfsson et al., 2001).   
In addition to Flt3 and CD34, angiopoietin-2 receptor (Tie-2) and the cell surface receptors of 
the signalling lymphocyte activation molecule family (SLAM), including CD150, CD244 and 
CD48, allow identification of more homogeneous populations within the KSL cells (Arai et 
al., 2004, Kiel et al., 2005).  The HSCs were purified as CD150+CD48-CD244- while MPPs 
were defined as CD150-CD48-CD244+ (Kiel et al., 2005).  However it is still debatable if the 
HSC population isolated by the SLAM markers can be compared to the ones isolated by using 
the Sca1, c-Kit and lineage markers (Weksberg et al., 2008).  Further it has been demonstrated 
7 
 
that HSCs expressing Tie-2 are the subpopulation that are more quiescent and so are enriched 
in the LT-HSCs.  Thus, Tie-2 allows the isolation of the most immature HSCs (Arai et al., 
2004).   
1.4.2 Haemopoietic stem cell identification using DNA binding dye Hoechst 33342 
In addition to surface markers, HSCs can be identified and isolated using the DNA binding 
dye Hoechst 33342.  HSCs have the ability to efflux this fluorescent dye via membrane 
transport pumps called ABC transporters.  These transmembrane proteins are present in many 
cell types with the function to remove different chemicals in the cytoplasm.  ABC-G2 is one 
of the protein members present in stem cells, and removal of the Hoechst 33342 dye can be 
observed with the flow cytometer by measuring red and blue fluorescent light emission after 
stimulating with a UV laser.  Stem cells show low red and blue fluorescence and appear as a 
so-called side population (SP) (Goodell et al., 1996).  Bone marrow cells displaying SP 
characteristic have been shown to have the capability of long term repopulation in lethally 
irradiated recipients.  Cells that lack the ability to expel the dye are called the major 
population (MP). 
1.4.3 Human HSCs 
 The isolation and characterisation of long-term reconstituting human HSCs is less well-
advanced than with the mouse HSCs and only 1 in 106 cells in the human bone marrow is a 
true transplantable HSC (Wang et al., 1997).  In humans, there are two main sources for HSCs 
that are being applied for therapeutic purposes; the bone marrow and the umbilical cord.  
CD34 is the most convenient cell surface marker for human HSCs and its discovery has 
helped in the study of human haemopoietic development.  This surface marker is expressed on 
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less than 5% of all blood cells and was the first marker found to enrich for human HSCs and 
progenitors (Civin et al., 1984).  In the nineties, the group of Baum et al and others proved 
that the human Lin- CD34+ cells were able to engraft in severe combined immunodeficient 
(SCID) mice and develop towards multiple lineages (Hao et al., 1998, Miller et al., 1999, 
Baum et al., 1992).  This assay measured the repopulating capacity of human stem cells.  
However, recent studies have shown that SCID-repopulating cell (SRC) activity resides in 
CD34- cells from human cord blood when transplanted using the intra-bone marrow injection 
method (Kimura et al., 2010).  To further define the phenotype of cord-blood derived CD34- 
SRCs, Kimura et al suggested that the immunophenotype of very primitive long-term 
repopulating human HSCs is Lin- CD34- c-Kit- Flt3-.  In addition Goodell et al have shown 
that CD34- cells exhibit side population characteristics like the mouse HSCs (Goodell et al., 
1997), whereas McKenzie et al have identified long-term human HSCs within the Lin- CD34+ 
CD38- population characterized by low retention of rhodamine 123 dye (McKenzie et al., 
2007).  Furthermore Baum et al identified CD90 (Thy1) as a further stem cell marker (Baum 
et al., 1992), while further studies introduced CD45RA and CD38 as markers of more 
differentiated cells; cells negative for these two markers are enriched in HSCs (Bhatia et al., 
1997, Conneally et al., 1997, Lansdorp et al., 1990).  Therefore, over the past decade human 
HSCs have generally been defined as CD34+CD38-Thy1+CD45RA-.  Further isolation of very 
immature human HSCs can be performed using flow cytometry to select for the expression 
levels of aldehyde dehydrogenase (ALDH), as it has been proven that haemopoietic 
progenitors exhibit high levels of this enzyme (Kastan et al., 1990).  Another important cell 
surface antigen that is expressed on the surface of long-term repopulating human HSCs is 
CD133.  This antigen has been shown to be expressed on several types of adult stem cells 
(Yin et al., 1997).   
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1.4.4 Bioassays of haemopoietic stem cells  
Assays have been developed to characterise haemopoietic stem and progenitor cells in vitro 
and in vivo. 
Short-term in vivo assays - The first in vivo assay to be developed for HSCs was the Spleen 
colony forming unit assay (CFU-S).  James Till and Ernest McCulloch demonstrated that 
colonies of myeloid cells developed in the spleen after injecting bone marrow cells into 
lethally irradiated mice (Till and McCulloch, 1961).  The CFU-S are therefore early 
engrafting cells, that allow the mouse to survive in the first 2-3 weeks post-transplantation 
when pancytopenia would otherwise occur following the irradiation.  The advantage of this 
assay is that it is short-term; usually around day 12 colonies can be counted in the spleen. 
Long-term in vivo assays - The gold standard assay that truly defines HSCs is the long-term 
reconstitution assay.  Lethally irradiated mice are injected with either the HSCs being tested 
or whole bone marrow cells, which is a reference non-selected population.  There are different 
types of long-term repopulation assays that measure the functional potential of HSC.  The 
competitive repopulation assay was developed by Harrison et al (1980) and measures the 
functional potential of test HSCs against whole bone marrow cells from congenic wild type 
mice (Harrison et al., 1993).  This study provides information about the function of the HSCs 
in their repopulation capacity compared to the competing bone marrow cells, but it does not 
provide any details about the progeny produced per HSC.   
The limiting dilution assay, another type of competitive repopulation assay, determines the 
frequency of the HSCs through a series of dilutions of the donor test cells that are competed 
against bone marrow cells (Szilvassy et al., 1990). 
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The most important assay to test the lifespan and the expansion limits of HSCs is the serial 
transplantation assay.  In this assay, HSCs are transplanted from the primary reconstituted 
recipient to a secondary irradiated host, thus demonstrating that engrafting cells are 
undergoing self-renewal and are able to sustain haemopoiesis.  In vivo assays are important 
for identifying and quantifying stem cell potential but they have limitations, due to the length 
of time required to monitor the mice after the transplantation and the significant number of 
mice that is used for the experiments and therefore the costs.   
Long-term in vitro assays - There are also a number of in vitro assays for measuring the 
frequency of progenitors and stem cells.  These include long-term culture-initiating cell (LTC-
IC), cobble-stone area forming cell (CAFC) and colony-forming unit in culture assays (CFU-
C) (Dexter et al., 1977, Whitlock and Witte, 1982, Sutherland et al., 1990, Ploemacher et al., 
1989).   
In CFU-C, immature cells like HSCs are grown in rich semisolid methylcellulose-based 
culture media, which allow the cells to differentiate along different pathways to give rise to 
more mature cell types.  The particular differentiation pathway depends on the presence of 
specific growth factors and nutrients within the culture conditions (Bradley and Metcalf, 
1966, Moore et al., 1973).  In CAFC and LTC-IC assays, HSCs are seeded and grown on a 
stromal layer, which mimics the natural HSC microenvironment.  The first assay measures the 
frequency of cells that are able to grow under the stromal layer as CAFCs.  The LTC-IC is 
very similar to the CAF-C assay, but the outcome is the presence of progenitor cells with 
colony-forming ability (Dexter et al., 1977). 
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1.5 Haemopoietic stem cell biology  
1.5.1 Haemopoietic stem cell fate choices 
Since Till and McCulloch proved the existence of HSCs in 1961, these have become the most 
extensively characterised stem cells.  HSCs, like any other stem cells have the ability to self-
renew symmetrically or asymmetrically.  When a HSC divides asymmetrically one of the 
daughter cells is able to retain the stem cell fate while the other daughter cell can embark on 
the pathway of differentiation to give rise to mature blood cell types.  In the case of 
symmetrical division, HSCs produce either two new stem cells or two differentiated cells.  
Self-renewal is an important property of HSCs, as sustaining these compartments is required 
for lifelong haemopoiesis.  HSC division is under strict physiological control.  For example, it 
is suggested that during embryonic development there is an increase in HSCs through 
symmetrical division, which expands the stem cell pool, while during adult tissue homeostasis 
asymmetrical division provides for self-renewal to sustain haemopoiesis and also 
differentiation to give rise to mature blood cells.  In cases of haemopoietic stress such as 
haemorrhage, it is suggested that HSC undergo symmetric division favouring differentiation 
to replenish the mature blood cells.   
In steady-state conditions, HSCs divide infrequently and usually do not enter the cell cycle.  
This non-dividing condition is called quiescence.  Preserving HSCs in a quiescent state and 
inhibiting them from differentiation is important for HSC maintenance and survival.  As this 
process suppresses cell division and therefore DNA replication, it also reduces the number of 
mutations that may occur during replication.  However, even if DNA mutations do occur in 
the quiescent state, HSCs would have enough time to repair the DNA damage.  Moreover  
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Figure 1.2: Haemopoietic stem cell fate choices. The figure shows the 
haemopoietic stem cell (HSC) fate decisions in the bone marrow.  Self-renewed 
and quiescent HSCs are shown in blue, apoptotic HSCs are represented in black 
while committed cells are in light blue. 
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quiescence protects HSCs from toxic drugs.  Quiescence of HSCs depends on the 
microenvironment within the bone marrow that is called the HSC niche.   
Another mechanism that might regulate HSC homeostasis in the body is apoptosis, the 
process of cell death without inflammation.  If there is an excess in HSC number, these cells 
would not divide but instead would undergo apoptosis to keep the required number in the 
body (Alenzi et al., 2009) . 
 
1.5.2 The haemopoetic stem cell niche 
HSCs are localised in the bone cavities of the bone marrow in a microenvironment that is 
referred to as the stem cell ‘niche’, as first proposed in 1978 by Schofield (Schofield, 1978).  
The bone microenvironment is composed of several potential niches with different specific 
cell types, the two best described are the osteoblastic (or endosteal) niche and the perivascular 
niche (Mitsiadis et al., 2007).  An essential function of the niches and the signals within them 
is regulating and maintaining the balance between self-renewal and differentiation, thus 
maintaining the HSC population and protecting it from excess self-renewal that might lead to 
cancer (Moore and Lemischka, 2006).  In the osteoblastic niche, osteoblasts seem to be the 
main cell type responsible for the signalling between stroma and HSCs, and this niche is 
thought to keep HSCs in a quiescent state.  A key interaction which has been linked with the 
maintenance of HSC quiescence is between angiopoietin-1 on osteoblasts and its receptor Tie-
2 on HSCs (Arai et al., 2004).  In order for these signal transduction exchanges to occur the 
two cell populations need to be in close contact with each other, and several adhesion 
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molecules have been reported to be necessary for this interaction, such as N-cadherin and 
SCF-Kit (Wilson and Trumpp, 2006).   
In comparison to the osteoblastic niche, the perivascular niche is thought to contain self-
renewing HSCs, which are important for rapid expansion and differentiation of blood cells 
(Wilson and Trumpp, 2006).  In the perivascular niche endothelial and the sinusoidal reticular 
cells are thought to be in contact with HSCs and to support HSC proliferation and 
differentiation (Kopp et al., 2005).  Also, the interaction between sinusoidal reticular cells 
expressing CXCL12 and HSCs expressing CXCR4 is reported to be important for HSC 
mobilization, homing and engraftment (Rafii et al., 1997, Sipkins et al., 2005).  Recent studies 
have been able observe in real time, at a single cell level the precise localisation of 
haemopoietic cells at different stages of maturity by using a combination of high-resolution 
confocal microscopy and two-photon video imaging (Lo Celso et al., 2009).  These studies 
could be used to define changes in the homing properties of stem cells that have been 
genetically modified.  
 
1.6 Leukaemic stem cells 
Leukaemia is a malignant disease of myeloid or lymphoid blood cells, characterised by rapid 
proliferation of abnormal cells, which in turn disturbs the homeostasis of the blood system.  
Leukaemias are generally divided into four categories: (i) Acute myelogenous leukaemia 
(AML); (ii) Acute lymphocytic leukaemia (ALL); (iii) Chronic lymphocytic leukaemia 
(CLL); and (iv) Chronic myelogenous leukaemia (CML).  Many haematological diseases 
have a stem cell component that has the capacity for indefinite self-renewal.  Bonnet and Dick 
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demonstrated that the AML cell population contains a subfraction of cells capable of 
transferring the disease to irradiated immunocompromised mice.  These cells were termed the 
leukaemic stem cells (LSC) (Bonnet and Dick, 1997).  A stem cell component has also been 
defined in CML (Jamieson et al., 2004), T-cell acute lymphoblastic leukaemia (T-ALL) (Cox 
et al., 2007), B-cell precursor ALL (Cox et al., 2004), and myeloma (Matsui et al., 2004).  In 
the last few years, various studies have shown that AML LSCs share key features with normal 
HSCs, which  include self-renewal ability and the quiescent cell cycle profile (Hope et al., 
2004, Guzman et al., 2002).  Although AML LSCs are phenotypically very similar to HSCs, 
being CD34+ / CD38- / HLA-DR-, there are three antigens that distinguish HSCs from AML 
LSCs, namely CD90, CD117 and CD123 (Blair et al., 1998). 
Three possible scenarios can be envisaged for the origin of LSCs within the haemopoietic 
hierarchy (Figure 1.3).  In the first, LSCs could be formed at the level of the HSC as the result 
of an initial mutation leading to a pre-leukaemic stem cell, followed by a secondary mutation 
that gives rise to the LSC.  In a second scenario, the initial mutation in the HSC leads to a pre-
leukaemic myeloid progenitor, in which a second mutation is required to generate the LSC.  
The third scenario requires normal HSC differentiation into myeloid progenitors, which are 
then the target for an initial mutation to form a pre-leukaemic myeloid progenitor that gives 
rise to the LSC after a second mutation (Jordan and Guzman, 2004).  
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Figure 1.3: Model for the origin of leukaemic stem cells (adapted from (Jordan 
and Guzman 2004)) In the first, LSCs could be formed at the level of the HSC as 
the result of an initial mutation leading to a pre-leukaemic stem cell, followed by a 
secondary mutation that gives rise to the LSC.  In a second scenario, the initial 
mutation in the HSC leads to a pre-leukaemic myeloid progenitor, in which a second 
mutation is required to generate the LSC.  The third scenario requires normal HSC 
differentiation into myeloid progenitors, which are then the target for an initial 
mutation to form a pre-leukaemic myeloid progenitor that gives rise to the LSC after 
a second mutation 
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1.7 Transcriptional regulation of haemopoiesis 
A number of transcription factors e.g SCL/TAL1, RUNX1, Mll, c-Myc, Pu.1, Tel/Etv6, Bmi-
1 have been found to be critical in the regulation of HSC establishment and maintenance at 
various stages of development (summarised in Figure 1.4).  Transcription factors not only 
play a decisive role in HSC development and homeostasis but also in determining the lineage 
fate from HSCs.  Each commitment step requires the activation of lineage-specific genes, 
whereas unnecessary genes are being repressed (Nerlov et al., 2000).  One of the very early 
regulators is the SCL/TAL1 (stem cell leukemia protein) that is required for blood cell 
formation.  It has been demonstrated that SCL knockout mice and ESC are not able to form 
haemopoietic cells nor are they able to express blood specific genes (Shivdasani et al., 1995, 
Robertson et al., 2000).  The generation of adult-type HSCs is dependent on the emergence of 
definitive haemopoietic precursor cell population and this process requires the presence of 
Runx1 (Runt-related transcription factor 1, also known as Acute Myelogenous Leukaemia 
factor 1, AML1) (Okuda et al., 1996).  Further, for the HSC to mature and to be functional in 
the foetus the Mll (mixed lineage leukemia) protein crucial.  Mll activates the expression of 
Hox genes which drive haemopoietic progenitor expansion (Ernst et al., 2004).  It has been 
demonstrated that Pu.1 is required for HSC-self-renewal and in addition controls the 
commitment of HSCs along some individual pathways; disruption of Pu.1 blocks the 
generation of CLPs and CMPs, demonstrating that Pu.1 is crucial for myeloid and lymphoid 
cell genesis (Iwasaki et al., 2005).  Another transcription factor that has been implicated in 
regulating the balance between adult HSC self-renewal and differentiation is the proto-
oncogene c-Myc.  c-Myc deficient mice show an increased number of HSCs due to impaired 
differentiation in all lineages (Wilson et al., 2004).  Moreover, Tel/Etv6 is a transcription 
factor that is necessary for maintenance of HSC survival (Hock et al., 2004), in this way 
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indirectly controlling HSC self-renewal and reconstitution capacity.  Bmi-1 is a 
transcriptional repressor that has been implicated in regulating HSC self-renewal ability (Park 
et al., 2003).  Bmi-1-/- mice die soon after birth due to a reduction in HSC number in the bone 
marrow (Park et al., 2003).   
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Figure 1.4: Examples of transcription factors that regulate the establishment and 
maintenance of HSCs at different stages of haemopoietic development (adapted 
from (Teitell and Mikkola, 2006)) 
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1.8 NF-!B signalling pathways 
NF-!B (nuclear factor !B) is another transcription factor that has been implicated in 
haemopoiesis, but its particular role in HSCs had not been defined.  However, the expression 
patterns of members of the NF-!B family suggest they are likely to play pivotal roles in 
haemopoietic differentiation.  For example, c-Rel expression is restricted to lymphocytes, 
monocytes, granulocytes and erythroid cells (Grossmann et al., 1999), RelB is expressed in 
dendritic cells and lymphocytes (Burkly et al., 1995), whilst the importance of NF-!B2 has 
been shown in expression has been shown in dendritic cells and lymphocytes  (Grossmann et 
al., 1999, Caamano et al., 1998). 
NF-!B transcription factors are involved in regulating and activating a wide variety of 
biological processes including: (i) the immune response; (ii) inflammatory process; (iii) cell 
stress response; (iv) cell cycle regulation; (v) cell differentiation; and (vi) cell survival 
(Campbell and Perkins, 2006) that will be further discussed in section 1.8.3 and 1.8.4. 
NF-!B can be activated through two main pathways: the Classical and the Alternative 
pathway 
1.8.1 NF-!B family transcriptional regulators 
The NF-!B family consists of five distinct members, namely NF-!B1 (the precursor p105 and 
the active protein p50), NF-!B2 (the precursor p100 and the active protein p52), RelA (p65), 
RelB and c-Rel.  Each protein contains a so-called Rel homology domain (RHD) which is 
responsible for dimerisation with itself and other family members and also for interactions 
with the inhibitors of NF-!B  (I!Bs) (Beg et al., 1995).  RelA, c-Rel, NF-!B1 and NF-!B2 
can form homo- and heterodimers with each other, whereas RelB can only dimerise with NF-
21 
 
!B1 and NF-!B2.  Each family member has a nuclear localisation signal (NLS) that allows 
the dimers to enter the nucleus.  Furthermore the members RelA, RelB and c-Rel each possess 
a transactivation domain, hence only dimers containing at least one of these proteins are able 
to induce gene transcription.  In contrast, NF-!B1 (p50) and NF-!B2 (p52) do not carry this 
domain, and as homodimers act as repressors (Caamano and Hunter, 2002).   
1.8.2 I!B and IKK family proteins 
In unstimulated conditions, NF-!B is localised in the cytoplasm and is inactive as a 
consequence of binding with members of the family of I!Bs, which includes I!B-$, I!B-#, 
I!B-%, and Bcl-3.  The I!B family of proteins is characterized by the presence of ankyrin 
repeats that bind to the RHD to block the NLS.  The precursor form of NF-!B1 and NF-!B2 
(p105 and p100 respectively) are also considered as members of the I!B family.  These 
proteins have ankyrin repeats in their C-terminal region that are able to fold back onto the 
RHD in the N-terminus, thereby masking the NLS and thus inhibiting their own nuclear 
localisation (Ghosh et al., 1998).   
Another family of proteins that is associated with NF-!B is the I!B kinase (IKK) family of 
serine kinases that phosphorylate I!B proteins and target them for degradation in order to 
transduce signals through NF-!B.  There are three members within this family of proteins: 
IKK$, IKK# and IKK& or NEMO.  IKK$ and IKK# are catalytic subunits of the complex 
whilst and IKK&/NEMO plays a regulatory role. 
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Figure 1.5: Rel/NF-!B family of transcription factors and inhibitors of NF-!B.  
In mammals there are five members of the Rel/NF-!B family of transcription factors: 
RelA, c-Rel, RelB, NF-!B1 (p105/p50) and NF-!B2 (p100/p52).  All five members 
share a Rel-homology domain (RHD).  RelA, c-Rel and RelB have transcriptional 
activation domains.  NF-!B1 and NF-!B2 are transcribed as the inactive precursors 
p105 and p100, respectively, which have a series of ankyrin repeats at the C-terminal.  
These proteins can also act as inhibitiors of NF-!B by dimerising with other 
members of the Rel/NF-!B family and retaining the complex in the cytoplasm.  
Phosphorylation and proteosomal degradation cleaves the ankyrin repeats from p105 
and p100 to produce the active p50 and p52 proteins, respectively.  The inhibitors of 
NF-!B (I!Bs) possess similar ankyrin repeats, and retain Rel/NF-!B dimers in the 
cytoplasm. 
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1.8.3 The classical NF-!B pathway  
The best studied NF-!B pathway is the classical pathway, which plays the main role in cell 
proliferation, apoptosis and pro-inflammatory responses (Beinke and Ley, 2004, Ghosh et al., 
1998).  This pathway is activated by pro-inflammatory cytokines such as TNF$ and 
interleukin-1 (IL-1) or microbial infections.  The typical NF-!B heterodimer in this pathway 
is RelA/p50, but c-Rel/p50 complex can also be involved.  In an unstimulated state these 
heterodimers are retained in the cytoplasm bound to I!B.  Upon stimulation, the classical 
pathway is activated through the IKK-mediated phosphorylation of I!B-$ at two serine 
residues (Ser32 Ser36) near the N-terminus of I!B-$ (Chen et al., 1995).  This leads to 
ubiquitination of Lys21 and Lys22 of I!B-$ by a specific ubiquitin ligase of the SCF family 
(Skp1/Cul1/F-box) (Karin and Ben-Neriah, 2000) and proteasomal degradation by the 26S 
proteasome (Scherer et al., 1995).  This results in the release of NF-!B into the nucleus where 
it binds to DNA and influences the transcription of target genes encoding cytokines, 
chemokines and adhesion molecules (Pahl, 1999).  The kinases responsible for the 
phosphorylation of I!B are a trimeric complex consisting of the catalytic subunits IKK$ and 
IKK# together with the regulatory subunit IKK&.   
1.8.4 The alternative NF-!B pathway 
The alternative pathway has been implicated in B-cell maturation and lymphoid development 
and immune processes such as promotion of adaptive immune responses.  The pathway is 
predominantly active in B-cells and occurs downstream of several TNF receptor family 
members, such as lymphotoxin # (LT#), B-cell activating factor receptor (BAFF-R) or CD40 
(Claudio et al., 2002, Berberich et al., 1994).  These stimuli activate NF-!B - inducing kinase  
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Figure 1.6: Activation of NF-!B. The classical and the alternative pathway.  The 
classical NF-!B pathway is activated by cytokines such as TNF" and interleukin-1 
(IL-1) or microbial infections and revolves around nuclear translocation of RelA/p50 
and c-Rel/p50 heterodimers, by degradation of I!Bs.  Activation of the classical NF-
!B pathway results in transcription of target genes including cytokines, chemokines, 
cell adhesion molecules and enzymes. In the alternative NF-!B activation pathway, 
signals triggered via CD40 or BAFF-R are mediated by NIK and IKK", which leads 
to p100 processing and subsequent nuclear translocation of predominantly p52/RelB 
heterodimers.  Activation of this pathway results in transcription of chemokines, 
cytokines and cell adhesion molecules.  
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(NIK), which in turn activates IKK$ to phosphorylate p100 bound to RelB in an inactive state 
in the cytoplasm.  Ubiquitination and proteolytic removal of the ankyrin-repeat containing 
domain in the p100 C-terminus at the glycine-rich hinge region (Heusch et al., 1999) allows 
the resultant p52/RelB dimer to enter the nucleus.  The p52/RelB heterodimer then drives 
transcription of several genes that are involved in developmental programmes in lymphoid 
cells (Dejardin et al., 1998, Yilmaz et al., 2003, Fusco et al., 2009).  The alternative pathway 
only occurs through NIK and IKK$, and does not depend on either IKK# or IKK& (Senftleben 
et al., 2001a).  
 
1.9 The role of NF-!B family proteins in lymphoid cell regulation 
To investigate the physiological roles of the different NF-!B proteins in vivo, especially in the 
regulation of the lymphoid system, several studies have utilised mice carrying deletions of 
individual or multiple NF-!B genes.   
Mice null for the nf!b1 gene are phenotypically normal and they are able to develop 
secondary lymphoid organs such as lymph nodes and Peyer’s patches, although the Peyer’s 
patches number is decreased (Paxian et al., 2002, Weih and Caamano, 2003).  However this 
subunit seems to plays a role in regulating responses of mature lymphocytes and also 
nonspecific immune responses to pathogens.  In nf!b1-/- mice, B cells are not able to 
proliferate in response to pathogens and are defective in antibody production (Sha et al., 
1995).  Also nf!b1-/- mice show an increase in B-cell apoptosis, as a result of a cell cycle 
block early in G1 (Grumont et al., 1998).   
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nfkb2 is mainly expressed in stomach epithelium and immune cells, and mice null for this 
gene exhibit minor defects in their splenic and lymph node architecture.  The spleen of these 
mice contains irregular follicular B-cell areas and there is a decreased B-cell number in the 
spleen, bone marrow and lymph nodes (Caamano et al., 1998).  In addition, mice lacking 
nf!b2 are impaired in their ability to produce antibodies to thymus-dependent antigens 
(Franzoso et al., 1998).  nf!b2 has been shown to play a role in the regulation of dendritic 
cells (DC) through its effect on RelB in the Alternative pathway.  Usually, RelB is retained in 
the cytoplasm in association with p100, however in mice lacking nf!b2 the loss of p100 
causes dramatically higher RelB activity that causes modified DC function (Speirs et al., 
2004).   
It is known that c-Rel is mainly expressed in immune cells and regulated accessory cells and 
plays a role in lymphocyte function.  In its absence B-cells do not proliferate due to a block in 
the cell cycle at the G1-stage and there is an increase in B cell apoptosis (Grumont et al., 
1998). 
Mice lacking RelA exhibit the most severe phenotype and die at ~E15 due to hepatocyte 
apoptosis induced by TNF-$ (Beg et al., 1995).  In relA-/- mice in which the TNF-$ pathway is 
inhibited, embryos are able to develop and to survive.  However, they die after birth due to 
increased susceptibility to microbial infections (Alcamo et al., 2001).  RelA protects several 
immune cells, and is involved in the regulation of anti-apoptotic genes (Beg and Baltimore, 
1996, Senftleben et al., 2001b).   
RelB is the only NF-!B component that is not able to bind DNA and forms active 
heterodimers with p50 or p52.  RelB is mainly involved in the formation of secondary 
lymphoid structures and in the development and function of T-cells (Gerondakis et al., 2006).  
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Usually RelB is expressed in lymphocytes and dendritic cells and therefore RelB-/- mice lack 
certain populations of dendritic cells (Wu et al., 1998, Burkly et al., 1995).  Also, the deletion 
of RelB causes defects in acquired and innate immune response (Weih et al., 1995).   
 
1.10 Association of NF-!B family proteins with haemopoietic stem cells and the leukemic 
stem cell phenotype 
Several studies have pointed to the significance of the NF-!B proteins in HSCs and LSCs.  
The study of Pyatt et al has shown that NF-!B is expressed in human CD34+ bone marrow 
cells and it might even be involved in the survival and colony formation of the cells (Pyatt et 
al., 1999).  In turn, its activation can be induced by several cytokines that are involved in the 
regulation of haemopoiesis.  NF-!B is required for the expression of several gene products 
that are important for haemopoiesis, such as interleukin-1" (IL-1") (Hiscott et al., 1993), 
TNF-# (Ziegler-Heitbrock et al., 1993), erythropoietin (EPO) (Lee-Huang et al., 1993), c-
myb (Toth et al., 1995) and more.  Increased NF-!B signalling is a distinctive feature of 
primitive umbilical cord blood CD34+ HSCs (Panepucci et al., 2007).  The same group 
recently showed that CD133+ cells, which define a more primitive subset among CD34+ 
HSCs, have a higher expression of many transcription factors including NF-!B.  By analysing 
promoter occupation of these transcription factors they revealed a higher frequency of NF-!B 
binding sites in genes such as RUNX1, GATA3 and USF-1, all of which play important roles 
in the regulation of the early stages of haemopoietic development (Panepucci et al., Panepucci 
et al., 2010). 
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Studies have also demonstrated that NF-!B proteins are constitutively active in many cancer 
cells, whether derived from solid cancers like breast cancer (Nakshatri et al., 1997) or 
haemopoietic cancers like acute lymphoblastic leukaemia (ALL), chronic lymphocytic 
leukaemia (CLL), acute myeloid leukaemia (AML) and multiple myeloma (MM) (Kordes et 
al., 2000).  Also, Guzman et al have observed constitutive activation of NF-!B transcription 
factor in primary AML LSCs linked to the survival of these cells (Guzman et al., 2001).  The 
anti-apoptotic activity of NF-!B proteins is thought to be critical in their role as survival 
factors in cancer cells (Wang et al., 1996, Wang et al., 1998).   
The reasons why NF-!B proteins are persistently active in tumour cells are not yet fully 
understood, but there are studies that may explain their involvement.  For example, oncogenes 
such as HRAS or BCR-ABL-1, together with positive regulators of NF-!B such as NIK 
protein, might undergo gain-of-function mutations that lead to continuous signalling to the 
IKK complex, thus causing constitutive activation of NF-!B.  Alternatively, permanent NF-
!B activity can be caused by mutations that occur in negative regulators involved in the 
pathway, thus preventing the NF-!B proteins to be switched off properly (Kim et al., 2006, 
Harhaj and Dixit, 2011, Staudt, 2010, Gilmore, 2007).  For example, inactivating mutations in 
I!B-# prevent retention of NF-!B proteins in the cytoplasm and initiate continuous activation 
(Krappmann et al., 1999)  
In contrast, inhibiting NF-!B causes apoptosis of cancer cells and LSCs.  Work from the 
Guzman laboratory has proven that treatment of LSCs with a combination of the proteasome 
inhibitor MG-132 and the anthracycline idarubicin induces a very rapid apoptosis of LSCs.  
Proteasome inhibitors are known to prevent NF-!B activation through effects on I!B, 
supporting the observation that NF-!B is involved in LSC survival (Guzman et al., 2002).  
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Fortunately, normal HSCs are resistant to these drugs and therefore survive (Gilliland et al., 
2004).   
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1.11 Hypothesis and Aims 
Hypothesis: 
NF-!B family proteins play a crucial role in maintaining the normal balance of HSC 
proliferation and survival.  Altering the expression of NF-!B proteins can lead to disruption 
of this balance, resulting in a transformed phenotype or aberrant stem cell function. 
Aims of the project: 
To assess the role of NF-!B family proteins in bone marrow HSCs 
Objectives: 
To assess the genetic ablation of NF-!B1 and NF-!B2 and the consequences on HSC number, 
phenotype and function  
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Cell lines 
2.1.1 HPC7  
HPC7 is a HSC-like cell line that has been generated by retroviral transduction of the LIM-
homeobox gene Lhx2 into haemopoietic progenitors derived from embryonic stem cells 
(Pinto do et al., 1998).  Lhx2 can immortalise both haemopoietic progenitors derived from 
embryonic stem cells as well as haemapoietic progenitor / stem cells obtained from adult 
mouse bone marrow (Pinto do et al., 2002).   
HPC7 cells at a density of 1x 106 cells/ml were maintained in Stem Pro medium (Invitrogen) 
supplemented with serum replacement (Gibco), 50 U/ml penicillin and 50 µg/ml streptomycin 
(Gibco), 12 µM L-glutamine (Invitrogen) and 50 ng/ml stem cell factor (Peprotech) at 37°C in 
an atmosphere of 5% CO2, 20% O2 and 75% N2. 
 
2.2 Mouse studies  
2.2.1 Mice and genotyping 
Both nf!b1-/- and nf!b2-/- mice were maintained on a C57BL6/J background. The nf!b1-/- 
mouse has been generated in the Sha et al laboratory. The PGK-neo cassette was inserted into 
exon 6 of the NFKB1 gene (Sha et al., 1995). The nf!b2-/- mice were generated by Caamano et 
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al by introduces the PGK-neo cassette into exon 4, disrupting the open reading frame of the 
gene (Caamano et al., 1998). The mice were genotyped by PCR using genomic DNA obtained 
from ear samples. The primers used for genotyping NF-!B1 mice were 3’WT50 
(GCAAACCTGGGAATACTTCATGTGACTAAG), 3’BS-7 
(ATAGGCAAGGTCAGAATGCACCAGAAGTCC) and 3’HH-Neo 
(AAATGTGTCAGTTTCATAGCCTGAAGAACG), which results in products of 120bp for 
the wild type allele and 200bp for the knockout allele.  The primers used for the NF-!B2 mice 
were 3’Ex4 (GCCTGGATGGCATCCCCG), 3’Ex5 (GTTTGGGCTGTTCCACAA) and 
3’PGK-1 (CCAGACTGCCTTGGGAAA), which result in products of 230bp for the wild 
type allele and 120bp for the knockout allele.  The primers were purchased from Eurofins 
MWG. 
To extract the genomic DNA, the ear samples were heated in 100 µl water at 95°C for 5 
minutes.  3 µl of 15 mg/ml proteinase K solution (Roche) was added and incubated at 37°C 
for 20 minutes.  The proteinase K was then inactivated by incubating at 95°C for 5 minutes.  1 
µl of genomic DNA, 0.5 µl of each primer at the concentration of 0.5 µM was added to 22.5 
µl of ReddyMix PCR MasterMix containing 2.5 mM magnesium chloride, deoxynucleotides 
and Taq polymerase.  The PCR products were amplified using the following thermal cycler 
parameters: denaturation at 95°C for 1 minute, followed by annealing at either 60°C for NF-
!B1 or 55°C for NF-!B2 for 1 minute and then extension at 72°C for another 1 minute.  This 
cycle was repeated 35 times.  The PCR products were analysed by electrophoresis on a 2.5% 
agarose gel in TAE and 0.5 µg/ml ethidium bromide (Sigma).   
2.2.2 Bone marrow preparation 
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Whole bone marrow was extracted from femurs and tibias of mice aged between 8 and 12 
weeks and flushed using 10 ml per mouse of Iscove’s Modified Dulbecco’s Medium (IMDM) 
(Invitrogen) containing 10% FBS through a 25 gauge needle.  Spleen cells were prepared by 
mincing the tissue in PBS supplemented with 10% FBS.  The cells were then filtered through 
a 70 'M cell strainer and were centrifuged for 5 minutes at 230 x g and the supernatant 
removed.   
The red cells were lysed in all stainings, except for Ter119/CD71/c-Kit, by adding 1 ml of 
ACK (Red Blood cell lysis buffer containing 0.15 M ammonium chloride, 1 mM potassium 
bicarbonate and disodium EDTA pH 7.3) per mouse and incubating at room temperature for 5 
minutes.  An equal volume of PBS was added to wash the cells, then the cells were 
centrifuged at 230 x g for 5 minutes, before re-suspending in IMDM containing FBS.   
For cell counting the samples were first resuspended in 1 ml of PBS supplemented with 10% 
FBS, then a 1 'l aliquot was further diluted in 100 'l of PBS and 10 'l 0.4% Trypan Blue 
(Sigma) was added.  10 'l of the dilution was mounted on a Neubauer Haemocytometer and 
counted under the microscope (Carl Zeiss, Axiovert 25). 
 
2.3 Cell analysis 
2.3.1 Immunofluorescent flow cytometry and cell sorting 
Stainings were performed in 100 µl IMDM containing 10% FBS.  200 µl of medium was then 
added prior centrifugation at 230 x g for 2 minutes at 4°C in a 96’V’ well plate.  To block 
non-specific binding, 4 'l of 5 µg/ml of anti-CD16/32 Fc-block (Fc&RII/III) (eBiosciences) 
was added to the cells and incubated on ice for 5 minutes.  Fc-block was not added to 
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stainings that required analysis with Fc&RII/III.   The primary antibodies were then added at a 
concentration of 10 µg/ml for 30 minutes and incubated on ice in the dark.  Single staining 
controls were done to setup the compensations between fluorescent channels.  The antibodies 
used are listed in Table 2.1.  To remove the excess antibodies, double the amount of medium 
was added prior to centrifugation at 198 x g for 3 minutes.  The supernatant was removed and 
the cells re-suspended in 100 µl medium per mouse.  The stained cells were analysed on a 
Cyan flow cytometer using Summit 4.3 software.   
For cell sorting, cells were first extracted from the bone marrow as described previously.  The 
red cells were lysed and the cells stained with the appropriate antibodies.  After washing the 
cells were re-suspended in 300 µl of IMDM containing 10% FBS.  The samples were filtered 
through a sterile 70 'M cell strainer and sorted on a MoFlo machine (Cytomation) into sterile 
IMDM containing 10% FBS for further usage. 
 
Primary antibody Conjugate Isotype Supplier Clone 
CD4 FITC, APC Rat IgG2b eBioscience RM4 -5 
CD5 FITC, APC Rat IgG2a eBioscience 53-7.3 
CD8a FITC, APC, PE Rat IgG2a eBioscience 53-6.7 
CD11b/Mac1 FITC, APC Rat IgG2b eBioscience M1-70 
CD16/32 PE Rat IgG2a eBioscience 93 
CD34 FITC, PE Rat IgG2a eBioscience RAM34 
CD41/61 PE Rat IgG1 eBiosciences MWReg30 
CD43 PE Rat IgM eBiosciences eBioR2/60 
CD45.1 PE-Cy5, PE, Pacific Blue Mouse IgG2a eBioscience A20 
CD45.2 FITC, PE, APC-Cy7 Mouse IgG2a eBioscience 104 
CD71 PE Rat IgG2a eBioscience R17217 
CD177 (c-Kit) PE-Cy5, APC Rat IgG2b eBioscience ACK2 
CD45R (B220) FITC, APC, Pacific Blue Rat IgG2b eBioscience HIS24 
Gr1 FITC, PE, APC Rat IgG2b eBioscience RB6-8C5 
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CD135 (Flt3) PE Rat IgG2a eBioscience A2F10.1 
Sca1 PE-Cy5, APC, Pe-Cy7, PE Rat IgG2a eBioscience D7. RUO 
Ter119 FITC, APC, PE Rat IgG1 eBioscience TER-119 
Table 2.1: Primary antibodies used for flow cytometric analysis and sorting of 
haemopoietic cells 
 
2.3.2 Side population staining 
Goodell et al described a procedure for staining the side population (Goodell et al., 1997).  
After counting, the bone marrow cells were re-suspended at 1x106 cells/ml in pre-warmed 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen) which contained 2% FBS 
(Bioclear) and 10 mM HEPES buffer (Invitrogen).  Hoechst 33342 (Sigma) dye was added to 
a final concentration of 5 µg/ml.  The cells were mixed and incubated in a 37°C water bath for 
90 minutes.  The cells were mixed every 15 minutes to ensure that the temperature of the cells 
was maintained at 37°C.  After the incubation the cells were centrifuged at 230 x g at 4°C for 
5 minutes.  The cells were re-suspended in ice-cold medium and stained with antibodies 
against lineage associated cell surface markers (CD5, CD8a, CD11b, Gr1, B220 and Ter119) 
c-Kit and Sca1.  Finally the cells were analysed using the MoFlo FACS machine.   
2.3.3 Cell cycle analysis of haemopoietic stem cells 
The cell cycle status of wild type and nfkb1-/- and nf!b2-/- mice were determined by BrdU 
(bromodeoxyuridine) staining.  For in vitro BrdU incorporation assay, KSL cells were sorted 
and plated in IMDM containing 10% horse serum (Sigma), L-glutamine (2 mM), penicillin 
(50 U/ml), streptomycin (50 'g/ml), murine SCF (20 ng/ml), FL (10 ng/ml) and TPO (5 
ng/ml) together with 25 'M BrdU (Sigma-Aldrich).  After 12 hours incubation at 37°C, the 
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cells were collected and centrifuged at 230 x g for 5 minutes.  The supernatant was removed 
and the KSL cells were resuspended in 100 'l PBS, followed by centrifugation onto glass 
coverslips.  The cells were then fixed in ethanol/acetic acid (75%:25%) for 20 minutes.  
Following fixation the cells were then incubated in PBS for 20 minutes and washed twice 
with demineralized water.  The KSL cells were denatured for 1 hour with 1 N HCL containing 
0.5% Tween-20 which is prepared on the day of the experiment.  The cells were washed twice 
with PBS and twice with the blocking buffer, that contains 5% FBS, 0.1%NaN3, PBS and 
0.1% Triton X-100 and treated with RNAaseA (100 'g/ml) in PBS at 37 ºC for 30 minutes.  
The cells were washed twice with the blocking buffer and incubated with the blocking buffer 
for 1 hour at room temperature.  The cells were finally incubated overnight with the primary 
monoclonal rat BrdU antibody (1:100 dilution, clone BU1/75, Abcam) at room temperature.   
The following day, the cells were washed 3 times with blocking buffer and 3 times with PBS 
and were then fixed with 4% paraformaldehyde in PBS for 10 minutes, washed twice with 
PBS and quenched 10 minutes 50 mM NH4Cl.  The cells were then washed again twice with 
PBS and twice with blocking buffer before being incubated for 2 hours with AlexaFluor anti-
rat IgG donkey (1:1000 dilution Invitrogen).  After washing 3 times with PBS, the cells were 
mounted using DAPI-containing Vectashield (Vector Laboratories).  At least two coverslips 
per sample were analysed.  The images were acquired by using the Zeiss LSM 510 Meta 
confocal fluorescence microscope (10 and 25 water immersion objective).  For the basic 
analysis of the confocal images, Zeiss LSM Image Browser v4.2 was used (Carl Zeiss Ltd). 
For the in vivo BrdU incorporation study, mice received 1 mg BrdU in 100 'l PBS via 
intraperitoneal injection.  After 24 hours the mice were sacrificed for analysis as described 
above. 
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2.4 Cell culture of haemopoietic stem cells 
2.4.1 Semisolid methylcellulose cultures of sorted KSL cells 
To assess individual cell proliferation and differentiation capacity 350 sorted KSL cells were 
plated into 1.5 ml methylcellulose Semisolid methylcellulose media supplemented with 25 
ng/ml thrombopoietin (TPO) (Methocult M3434, Stem cell Technologies, Vancouver).  The 
sorted KSL cells were added, vortexed gently and finally plated in a 35 mm Petri dish using 
an 18-gauge needle.  At least duplicates were plated in each experiment.  Colony numbers and 
phenotypes were assessed at day 7.  For secondary and successive replatings, all cells from 
previous replating were collected by diluting the methylcellulose with PBS and pippeting it 
from the plate into a 10 ml falcon tube, cells were counted and 5000 cells replated in fresh 
methylcellulose.  All cultures were incubated at 37ºC in a fully humidified 5% CO2 in air 
atmosphere.  For identification of colonies, colonies were picked with a pipette tip, and 
resuspended in 100 µl PBS, which was loaded into cytospin funnels (Shandon) for 
centrifugation.  Cells were centrifuged for 8 minutes at 23 x g onto microscope slides (BDH) 
and air-dried.  Slides were further stained using Diff-Quick set of stains (Dade Behring) for 
differential staining of cytospins.  Cytospins were dipped f15 times for 1 second into the 
following three solutions: i) 2 µg /ml Fast Green methanol, ii) 1.22 mg/ml Eosin G in 
phosphate buffer (pH 6.6) and iii) 1.1 mg/ml Thiazine Dye in phosphate buffer (pH 6.6).  
Using paper towels excess fluid was drained between each solution.  Finally the slides were 
washed gently with distilled water, air dried and covered with neutral mounting medium 
(BDH) and cover glass. 
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2.5 Competitive bone marrow reconstitution assay 
One week before transplantation, recipient animals were treated with Baytril antibiotic.  
Following transplantation, the antibiotic was given until the body weight of the mice was 
stable.  For competitive repopulation assays, recipient mice (B6:SJL, CD45.1/CD45.1) were 
lethally irradiated (900 Gy) and injected via the tail vein with 1 x 106 reference wild type 
ACK-treated whole bone marrow cells (B6 x B6:SJL F1, CD45.1/CD45.2) together with 500 
sorted KSL donor cells from either wild type or nf!b knockout mice (C57BL6/J, 
CD45.2/CD45.2) (Figure 2.1).  The reference cells were used as an internal reference and also 
served to keep the mice alive after irradiation.  Every four weeks until six months post-
transplantation, blood samples were taken from the tail vein to assess reconstitution by the 
donor cells.  Using antibodies against CD45.1 and CD45.2 enabled discrimination of the 
donor and reference cells.  After 6 months the mice were sacrificed and the bone marrow cells 
analysed by immunofluorescent flow cytometery. 
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Figure 2.1: Transplantation of wild type and nf!b knockout KSL cells into lethally 
irradiated recipients: recipient mice (B6:SJL, CD45.1/CD45.1) were lethally irradiated (900 
Gy) and injected via the tail vein with 1 x 106 reference wild type ACK-treated whole bone 
marrow cells (B6 x B6:SJL F1, CD45.1/CD45.2) together with 500 sorted KSL donor cells 
from either wild type or nf!b knockout mice (C57BL6/J, CD45.2/CD45.2). Every four weeks 
until three to six months post-transplantation, blood samples were taken from the tail vein to 
assess reconstitution by the donor cells.  Using antibodies against CD45.1 and CD45.2 
enabled discrimination of the donor and reference cells.  After three to six months the mice 
were sacrificed and the bone marrow cells analysed by immunofluorescent flow cytometery. 
 
2.6 RNA analysis 
2.6.1 RNA extraction 
After KSL cells were sorted they were centrifuged at 230 x g for 5 minutes at 4ºC and 
resuspended in 250 'l TRIZOL Reagent (Invitrogen).  The lysates were either stored at -20ºC 
or processed immediately as indicated by the manufacturer by adding 0.2 volumes of 
chloroform (Sigma) per sample and shaking vigorously by hand for 15 seconds.  The lysates 
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were incubated for 5 minutes on ice and then micro-centrifuged at 17900 x g for 15 minutes at 
4ºC.  The upper aqueous phase was collected into a fresh RNase-free tube.  To aid RNA 
precipitation 1 'l of RNase-free glycogen (Roche) was added together with 0.5 volumes of 
isopropanol (Sigma).  The samples were centrifuged at 17900 g for 10 minutes at 4ºC, air-
dried and resuspended in 10 'l of RNase-free water.   
2.6.2 cDNA synthesis 
The single-stranded cDNA was prepared by first adding 1 'l of 500 ng/'l of oligo (dT) 
primers and 2 'l of 0.5 mM dNTPs (Roche) to 10 'l RNA and incubating at 65ºC for 5 
minutes.  Samples were then placed on ice for 1 minute, 4 'l of 5x First-strand buffer 
(Invitrogen), 1 'l dithiothreitol (10nM, Invitrogen), 1 'l RNase-out and 1 'l Superscript 
reverse transcriptase (Invitrogen) were added to the mixture and reverse transcription was 
carried out for 1 hour in a 50ºC water bath, followed by the inactivation of the enzymes at 
70ºC for 15 minutes.   
2.6.3 Semi-quantitative RT-PCR 
By measuring the expression level of the housekeeping gene hypoxanthine guanine 
phosphoribosyl transferase (HPRT) using real time PCR the cDNA samples were normalised.  
PCR reactions were performed in a final volume of 50 'l Reddy Mix PCR Master Mix 
(ABgene) containing appropriate concentrations of gene-specific oligonucleotides (Table 2.3) 
using the MJ Research PTC100/200 machines.  The PCR products were amplified using the 
following thermal cycler parameters: denaturation at 95°C for 40 secs, followed by annealing 
at 50-60°C (can vary, depend on the primers) for 40 secs, and extension at 72°C for 40 secs.  
For each PCR reaction, samples were taken at intervals of 3 cycles to estimate the linear phase 
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of amplification.  The PCR products were analysed by electrophoresis on 2.5% agarose gels.  
The experiment was performed in duplicate. 
Gene Forward primer Reverse primer Tanneal (°C) 
PCR 
Product 
size 
HPRT CCTGCTGGATTACATCAAAGCACTG 
GTCAAGGGCATATCCTACAAC
AAAC 59 620 
NF-!B 1 GATAACCTCTTTCTCGAGAAGGCTC 
TCCCCATTCTCATCCTGCACG
GCGG 60 233 
NF-!B 2 GCCTGGATGGCATCCCCG CTTCTCACTGGAGGCACCT 60 193 
RelA GAGAGAAGCACAGATACCACCAAGAC 
GGTTATCAAAAATCGGATGTG
AGAGG 60 415 
RelB 
ATGCCGAGTCGCCGCGCTG
CCAGAGATGCTCTGTGATG
ACCAGGTAC 
AAGCGCATGCCACGCTGCTTT
GGCGTCCGCGCCCGAGCTAGG
G 
60 352 
c-Rel 
TGGCTGACTGACTCACTGA
CTGACTGACTCGTGCCTTG
C 
CCAACTAAATCATGAGGATGA
GGCTTATATGGATCATTC 60 263 
I!B$ CAGGACTGGGCCATGGAGGG TGGCCGTTGTAGTTGGTGGC 60 526 
I!B#  CCCTTCCTGGATTTCCTCCTGGGCTTTTC 
GTGGGGTCAGCACCGGCTTTC
AGGAGA 60 589 
Table 2.2: Sequences of semiquantitative RT- PCR oligonucleotide primers 
 
2.6.4 Real time PCR 
The real time PCR reactions were performed using SYBR Green and the gene-specific 
primers.  Primers were designed using the Primer Express Software (MWG Biotech) to span 
an intron, generating products between 100-300 bp and no unspecific product, such as primer 
dimers.  Different concentrations of the primers were tested on serial dilutions of cDNA 
samples to confirm the efficiency of the primers and the validity of the assay.  For each 
reaction 1-2 'l of cDNA dilutions were used in an 18 'l of reaction with Absolute QPCR 
SYBR Green Mix (ABgene) and 200-400 nM of each primer.  The reactions were performed 
and analysed on the Stratagene Real time PCR machine using the following thermal cycler 
parameters: an initial denaturation step (95ºC/ 15 minutes), cycling included 95ºC for 15 sec, 
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57-60ºC for 20 sec and 72ºC for 20-30 sec(40 cycles) (Stratagene Mx3005P).  The MxPro 
software of the Stratagene Real Time PCR machine calculated the amplification efficiency 
and the Ct-value of each sample.   
Gene Forward Primer Reverse Primer Tanneal (°C) 
HPRT TGGACTGATTATGGACAGGAC AGGGCATATCCAACAACAAAC 60 
NF-!B1 ACATGGTGGTTGGCTTTGC CCCTAATACACGCCTCTGTCATC 60 
NF-!B2 GGGCCGGAAGACCTATCCTA ACGAGGTGGGTCACTGTGTGT 60 
RelA AAGCCATTAGCCAGCGAATC GCCCGGTTATCAAAAATCGG 60 
c-Rel CAGAATTTGGACCAGAACGCA TGCTGTTCAGGGACATTGAAAG 60 
Table 2.3: Sequences of RT- PCR oligonucleotide primers 
 
2.7 Statistical Analysis  
Statistical analyses were performed using unpaired two-tailed t test.  For all tests, a p value 
lower than 0.05 was considered statistically significant. 
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CHAPTER 3 
ANALYSIS OF THE ROLE OF NF-!B1 IN HAEMOPOIETIC 
STEM CELLS 
3.1 Introduction 
As detailed in Chapter 1, NF-kB activity has been implicated in HSC survival and 
development, however, it was not known which members of this transcription factor family 
played significant roles in these stem cells nor were their precise functions defined.  To study 
the importance of NF-!B1 function in HSC in greater detail, I have used gene knockout mice 
of NF-!B1 and performed in vitro and in vivo assays to assess the HSCs function and 
compared them to those obtained from the wild type cells.  Using PCR we detected NF-!B1 
in HSCs. To study the function of NF-!B1 in HSCs in vivo we performed serial 
transplantation assays. For in vitro study we performed colony formation assays and 
proliferation assays were performed. 
 
3.2 The expression of NF-!B family members in HPC7 and KSL cells 
In order to gain some understanding of the expression pattern of NF-!B family members in 
HSCs, semi-quantitative real-time PCR analyses were performed on RNAs derived from the 
HSC-like cell line, HPC7, and from sorted primary KSL cells.  These analyses revealed 
clearly detectable expression of NF-!B1, NF-!B2, and RelA in HPC7 cells and of NF-!B1, 
NF-!B2 and RelA in KSL cells (Figure 3.1A and B).  RelA appears to be the most abundantly
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Figure 3.1: Gene expression analysis of the NF-!B family members in HPC7 and 
KSL cells.  (A) The panel shows the expression of different NF-!B family members 
in HPC7 cells.  cDNA was prepared from extracted RNA and semi-quantitative PCR 
analysis was performed.  cDNA was normalised against the HPRT gene as a positive 
control.  The PCR reactions were sampled at cycles 23, 26, 29.  (B) The panel shows 
the expression of the NF-!B family members in sorted KSL cells from the bone 
marrow of wild type C57BL6 mice.  PCR reactions were sampled at cycles 27, 30, 
33.  (C) Real time PCR was performed on cDNA samples of HPC7 cells as described 
in (A) using SYBR Green and primers specific for the NF-!B family member genes.  
Normalisation was performed against HPRT.  Reactions were repeated at least 3 
times.  The normalised average fold-change expression values are shown.  Error bars 
represent the SEM. 
(A) (B) 
(C) 
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expressed NF-!B family gene in HSCs.  c-Rel was detected in HPC7, but at a lower level, and 
was barely detectable in KSL cells.  RelB could not be detected in either HPC7 or KSL cells 
unless the number of amplification cycles was significantly increased (data not shown).   
NF-!B1 and NF-!B2 are expressed in HSCs and subsequent work described in this and the 
next chapter was directed towards understanding their significance in these cells. 
 
3.3 Comparison of haemopoietic cells in the bone marrow of wild type versus nf!b1-/- 
mice 
In order to study the effect of the transcription factor NF-!B1 in multiple haemopoietic 
lineages, an analysis of different haemopoietic cell types in the bone marrow of wild type 
mice was performed and compared to bone marrow from nf!b1-/- mice.  The study of different 
haemopoietic cell types was done using immunofluorescent staining for specific lineage-
associated markers.  Using lymphoid markers for B-cells (B220/CD43) and T-cells 
(CD4/CD8) it was clear that nf!b1-/- mice exhibit no difference in their lymphoid cell number 
compared to the wild type mice.  Staining for myelomonocytic markers (CD11b/Gr-1) also 
revealed no difference in the cell number between wild type and nf!b1-/- mice.  Further 
immunofluorescent staining of nf!b1-/- mice with antibodies against the red cell markers 
Ter119 and CD71 showed equivalent erythroid cell numbers compared to the wild type mice.  
Finally, staining with antibodies recognising the progenitor-associated SCF receptor c-Kit and 
the stem cell/megakaryocyte alpha integrin GPIIb (CD41) showed no change in the progenitor 
numbers committed towards megakaryocytic differentiation (Table 3.1 and see Appendix 
Figure A1 and A2).  
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Cell type Surface markers Wild type versus nf!b1 knockout 
Lymphoid 
B220/CD43 (B-cells) 
CD4/CD8 (T-cells) 
Equivalent 
Myelomonocytic CD11b/Gr1 Equivalent 
Erythroid TER119/CD71/c-Kit Equivalent 
Megakaryocytic c-Kit/CD41 Equivalent 
Table 3.1: Immunofluorescent analysis of bone marrow cells from wild type versus 
nf!b1-/- mice.  Bone marrow was flushed from the femur and tibias of mice aged 8-10 weeks.  
The table represents different surface markers that were used to study the different 
haemopoietic lineages. (n=6) 
 
3.4 Analysis of the progenitor and haemopoietic stem cell compartment in wild type and 
nf!b1-/- mice 
The progenitor and HSC compartments of wild type and nf!b1-/- bone marrow were analysed 
using a cocktail of antibodies against lineage-associated markers (CD5, CD8a, CD11b, Gr-1, 
B220 and Ter119) combined with antibodies against progenitor-associated SCF receptor, c-
Kit and stem cell antigen Sca-1.  The different myeloid progenitor populations can be studied 
in the Sca1 negative portion of the KSL, which can be further subdivided into (i) GMP 
(CD34+CD16/32+); (ii) CMP (CD34-CD16/32+); and (iii) MEP (CD34-CD16/32-).  The 
markers CD34 and Flt3 can be used to separate the KSL compartment into; (i) LT-HSCs 
(CD34-Flt3-); (ii) ST-HSCs (CD34+Flt3-); and (iii) multipotent progenitor (MPP) cells 
(CD34+Flt3+).   
Staining with lineage markers revealed a small increase of lineage negative cells in the nf!b1-
/- bone marrow mice.  However, further analysis of several animals showed that there is a  
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Figure 3.3: Immunofluorescence analysis of progenitor cells of wild type and 
nfkb1-/- mice.  To analyse the GMP, CMP and MEP populations, wild type (WT) and 
nfkb1-/-  (KO) Lin-c-Kit+Sca-1- cells were co-stained with antibodies against CD16/32 
(Fc! receptor) and CD34.  (A) Two-dimensional dot plots of cells gated on FSC 
against SSC (live cell gate), lineage antigen  negativity, and on c-Kit+Sca-1-. The 
GMP, CMP and MEP cells are indicated by the gates.  The schematic indicates the 
position of the GMP, CMP and MEP populations.  (B) The histograms represent the 
average percentage of GMP, CMP and MEP cells from wild type and nfkb1-/- mice.  
The bars indicate the SEM (n=6). * indicates significance (P<0.05) 
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tendency towards more lineage negative cells in the knockout bone marrow compared to the 
wild type, but this difference is not statistically significant (Figure 3.2A).  No difference was 
observed in the Lin-c-Kit+Sca-1- population, which contains GMPs, CMPs, and MEPs (Figure 
3.2B).  However, analysing these progenitor populations separately by co-staining with 
antibodies against CD34 and CD16/32 showed that there was a significant decrease in GMP 
and CMP population in the nf!b1-/- mice, while the MEP population was significantly 
increased (Figure 3.3).  This result suggests that there might be a decrease in the proportion of 
more mature myeloid cells and an increase in the erythroid cell proportion in the nf!b1-/- mice.  
However, analysis of these mature cells using cell surface markers revealed that this is not the 
case that might be due to homeostatic adjustments. 
Further study of the KSL population of the nf!b1-/- mice indicated that there is an at least a 7-
fold increase in this population compared to the wild type mice.  The total number of bone 
marrow does not change between wild type and knockout mice.  However the absolute 
number of KSL cells is increased mirroring the increased percentage.  Since it is known that 
the murine bone marrow KSL fraction consists of a heterogeneous population of cells with 
different repopulation capacity when transplanted into lethally irradiated mice, the KSL cells 
were subdivided into three different compartments based on their expression of CD34 and the 
fms-like tyrosine kinase receptor, Flt3.  Co-staining of wild type and nf!b1-/- bone marrow 
cells with antibodies against KSL markers, CD34 and Flt3 revealed that there are no major 
differences in the proportion of the KSL sub-populations in the knockout mice compared to 
the wild type.  Knockout mice show a slight increase in the proportion of CD34- Flt3- KSL 
cells, however, this was not statistically significant (Figure 3.4).  Although there is no 
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significant difference within the KSL compartment, corresponding to the increase of the KSL 
absolute numbers the LT-, ST-HSC and MPP absolute numbers are also increased.  
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Figure 3.3: Immunofluorescence analysis of progenitor cells of wild type and 
nfkb1-/- mice.  To analyse the GMP, CMP and MEP populations, wild type (WT) and 
nfkb1-/-  (KO) Lin-c-Kit+Sca-1- cells were co-stained with antibodies against CD16/32 
(Fc! receptor) and CD34.  (A) Two-dimensional dot plots of cells gated on FSC 
against SSC (live cell gate), lineage antigen  negativity, and on c-Kit+Sca-1-. The 
GMP, CMP and MEP cells are indicated by the gates.  The schematic indicates the 
position of the GMP, CMP and MEP populations.  (B) The histograms represent the 
average percentage of GMP, CMP and MEP cells from wild type and nfkb1-/- mice.  
The bars indicate the SEM (n=6). * indicates significance (P<0.05) 
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Figure 3.4: Immunofluorescence analysis of stem cell compartments of wild type 
and nfkb1-/- mice.  Bone marrow from wild type (WT) and nf!b1-/- (KO) mice was 
extracted and the red cells were lysed.  (A) Two-dimensional dot plots showing c-Kit 
and Sca1 staining of cells gated on FSC against SSC (live cell gate) and lineage 
antigen negativity.  The gate shown represents the KSL fraction.  (B) The histogram 
represents the average percentage of KSL cells from WT and KO mice.  The bars 
indicate the SEM. * indicates significance (P<0.05) (C) KSL cells co-stained with 
Flt3 and CD34.  The two dimensional dot plot represents KSL gated cells.  The 
schematic indicates the position of long-term (LT) HSC, short-term (ST) HSC and 
multipotential progenitors (MPP).  (D) The histogram represents the average 
percentage of cells within each gate.  The bars show SEM (n=6).  
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3.5 Analysis of wild type versus nf!b1-/- KSL cells using a phenotypic assay of stem cells  
Goodell et al used the Hoechst 33342 DNA binding dye as a means to define the HSC 
population in murine bone marrow.  Stem cells express the ABC-G2 protein, an ABC 
transporter, which has the ability to export dyes such as Hoechst 33342 that have entered the 
cytoplasm by passive diffusion.  The expression of this transporter protein is thought to 
correlate with the immaturity of the cell type, the more immature the cells are, the higher the 
expression of the ABC-G2 transporter protein.  Hoechst 33342 dye was used to evaluate the 
proportion of immature HSCs in wild type compared to nf!b1-/- mice.  Red cells were lysed 
and the remaining cells were co-stained with Hoechst 33342 and the antibodies defining the 
KSL population (Goodell et al., 1997).  It is known that the side population (SP) that excludes 
Hoechst 33342 includes quiescent, immature stem cells.  KSL cells in wild type and nf!b1-/- 
bone marrow mice were gated and the proportion of the cells within the SP gate was assessed.  
This analysis revealed a significant decrease in the percentage of KSL cells that fell within the 
SP in the nf!b1-/- mice.  However, there was no significant difference in the proportion of 
KSL cells within the main population (MP) (Figure 3.5A and B).  This would suggest that 
there is a decrease in quiescent HSCs within the bone marrow of nf!b1-/- mice.   
 
3.6 Comparative analysis of properties of wild type and nf!b1-/- bone marrow HSCs  
3.6.1 Cell cycle analysis of wild type and nf!b1-/- bone marrow haemopoietic stem cells 
Since it is believed that the side population includes quiescent HSC, and the SP analysis 
showed a decrease of nf!b1-/- KSL cells within this fraction, we decided to study the cell cycle 
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status of wild type and nf!b1-/- HSCs in order to gain some understanding about their 
proliferative capacity.  BrdU incorporation assays were performed in vitro and in vivo.   
For the in vitro BrdU incorporation assay, KSL cells from the bone marrow of wild type and 
nf!b1-/- mice were sorted and plated in IMDM containing BrdU (section 2.2.3.2) at 37ºC.  
After labelling with BrdU, the cells were collected, fixed and incubated overnight with 
primary rat anti-BrdU antibody.  The cells were finally stained with secondary Alexa 
Fluor488 labelled anti-rat IgG and mounted using DAPI-containing Vectashield.  Cells that 
were positive for BrdU, as viewed by confocal microscopy, were counted as proliferating 
KSL cells.   
For the in vivo BrdU incorporation assay, BrdU was injected intra-peritoneally into the mice 
which were then sacrificed after 24 hours.  Bone marrow cells were sorted for KSL cells, 
followed by staining with antibodies as described for the in vitro BrdU assay.   
The in vitro BrdU incorporation assay (Figure 3.6A) showed that there was a small increase in 
the percentage of BrdU positive KSL cells in nf!b1-/- compared to the wild type.  However, 
this increase was not statistically significant as there was a high degree of variation from 
mouse to mouse.  The in vivo BrdU incorporation assay showed no differences in the 
proliferative capacity of the nf!b1-/- compared to the wild type KSL cells (Figure 3.6B).   
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Figure 3.5: Analysis of bone marrow from wild type and nf!b1-/- mice using the 
DNA binding dye Hoechst 33342. (A) The bone marrow of wild type (WT) and nf!b1-/- 
(KO) mice of 8-10 weeks of age was extracted and the red cells lysed. Cells were then 
stained with Hoechst 33342 as previously described (Goodell et al., 1997) and 
subsequently co-stained with a cocktail of antibodies against lineage-specific surface 
markers (CD5, CD8a, CD11b, Gr1, Ter119 and B220) and the stem cell markers c-Kit and 
Sca-1. The Hoechst 33342 profile analysis was performed following gating for forward 
scatter (FSC) versus side scatter (SSC), focussing on the lineage negative and KSL 
fractions. The schematic indicates the position of the side population (SP) and the major 
population (MP). (B) The histogram represents the average percentage of cells in the SP 
and the MP gate with bars indicating the SEM (n=4). * indicates significance (P<0.05) 
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Figure 3.6: Analysis of the proliferation of HSCs from wild type and nf!b1-/- mice. 
(A) Bone marrow cells from wild type (WT) and nf!b1-/-  (KO) mice at 8-10 weeks of 
age was extracted and the red cells lysed. KSL cells were sorted and placed in a liquid 
culture for 12 hours in IMDM containing BrdU. After labelling, the cells were collected, 
fixed and denatured. After blocking, the cells were incubated overnight with the primary 
monoclonal rat anti-BrdU antibody. One day later the cells were washed and fixed with 
paraformaldehyde and quenched with NH4Cl and finally incubated for 2 hours with 
AlexaFluor 488 donkey anti-rat. The cells were mounted with DAPI-containing 
Vectashield and images were acquired using the Zeiss LSM 510 Meta confocal 
fluorescence microscope. (B) For in vivo BrdU incorporation assay, mice were injected 
intra-peritoneally with BrdU and sacrificed after 24 hours. Bone marrow cells were 
sorted for KSL cells, and stained as described in (A) (n=4) P>0.05 
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3.6.2 Colony forming potential 
In order to compare the proliferation and differentiation potential of wild type and nf!b1-/- 
HSCs in vitro, colony assays were performed using sorted KSL cells.  On first plating, both 
wild type and nf!b1-/- KSL cells formed approximately the same number of colonies (Figure 
3.7A), the small decrease in nf!b1-/- colonies mirrors the slight decrease in the total number of 
cells recovered from the tissue culture plates (Figure 3.7C).  After performing several 
independent experiments, it was concluded that there were no significant changes in the 
generation of colony types (Figure 3.7 B, D and E).  Upon secondary replating, the colony 
forming capacity of the nf!b1-/- cells was significantly impaired compared to the wild type, 
giving rise to 2.4-fold fewer colonies than the wild type KSL cells (Figure 3.8A).  Moreover, 
the size of colonies was smaller with nf!b1-/- cells compared to the wild type (Figure 3.8C), 
which was also reflected in the total number of cells recovered from the tissue culture plates 
(Figure 3.8B).  On tertiary replating, nf!b1-/- cells were not able to form proper colonies and 
instead spread over the plate.  These looked more dispersed and differentiated (Figure 3.9B), 
and this explains the high number of cells that was collected from the nf!b1-/- plates (Figure 
3.9A).  In contrast, the wild type cells retained their clonogenic potential. 
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Figure 3.7: Analysis of the primary colony forming potential of wild type and nf!b1-/- 
KSL cells. 350 KSL cells of wild type (WT) and nf!b1-/- (KO) mice were plated in 
semisolid methylcellulose medium (Methocult M3434) supplemented with TPO. (A and 
B) Histograms show the number and morphology of colonies counted after 7 days. (C) 
For assessment of the total number of cells within each plate all cells were collected and 
counted. (D) Pictures of colonies were taken at 5x magnification. (E) Following cytospin, 
cells were stained with Diff-Quick (n=5) P>0.05. !
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Figure 3.8: Analysis of secondary colony forming potential of wild type and nf!b1-/- 
KSL cells. For secondary replating all cells primary colony assay plates were collected, 
counted and 5000 cells were replated in fresh methylcellulose, and number of colonies 
and number of cells was assessed after 7 days. All cultures were incubated at 37°C in a 
fully humidified 5% CO2 in air atmosphere. (A) Histograms show the number of 
colonies counted after 7 days. (B) For assessment of the total number of cells within 
each plate all cells were collected and counted. (C) Pictures of colonies were taken at 5x 
magnification. * indicates significance (p<0.05) 
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Figure 3.9: Analysis of tertiary colony forming potential of wild type and nf!b1-/- 
KSL cells. For tertiary plating, all cells from secondary colony forming assay plates were 
collected, counted and 5000 cells replated in fresh methylcellulose and number of 
colonies and number of cells were assessed after 7 days. All cultures were incubated at 
37°C in a fully humidified 5% CO2 in air atmosphere. (A) The histogram shows the 
number of colonies within each plate. (B) For assessment of the total number of cells 
within each plate all cells were collected and counted. (C) Pictures of colonies, taken at 
5x magnification. * indicates significance (p<0.05) 
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3.7 RNA analysis 
The mild phenotypic differences seen in the nf!b1-/- KSL cells suggest that the continued 
expression of the other NF-!B family members might partially compensate for the absence of 
NF-!B1.  To assess this, expression of the other NF-!B genes was assessed.  RT-PCR 
analysis (Figure 3.10) revealed that nf!b1 gene deletion increased c-rel expression by up to 6-
fold in KSL cells.  In contrast, nf!b2 gene expression was hardly affected, whereas the relA 
gene appeared to be expressed at lower levels in the nf!b1-/- KSL cells compared to the wild 
type. 
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Figure 3.10: Expression of NF-!B family genes in wild type versus nf!b1-/- KSL 
cells. RNA was extracted from KSL cells from the bone marrow of wild type and 
nf!b1-/- mice and converted into cDNA. Real time PCR was then performed on the 
cDNA using SYBR Green and primers specific for the nf-!b family members. The 
cDNA was normalised using the HPRT gene as a control. The figure represents results 
obtained from two experiments and shows the abundance in nf-kb1 knockout cells 
relative to the wild type. Each PCR was performed in triplicate and the error bars 
represent the SEM.  
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3.8 Assessment of nf!b1-/- HSC function by transplantation into lethally irradiated 
recipients 
The gold standard test of HSC function is to demonstrate their ability to reconstitute lethally 
irradiated recipient mice.  Furthermore, by performing transplantations using combinations of 
wild type and mutant KSL cells, it is possible to assess the relative HSC potency. 
Recipient mice (BoyJ CD45.1/CD45.1) between 8-10 weeks in age were lethally irradiated 
(900 Gy) and injected via the tail vein with 106 whole bone marrow reference BoyJ:B6F1 
CD45.2/CD45.1 cells and 500 sorted KSL donor cells either from wild type or nf!b1-/- mice 
(B6 CD45.2/CD45.2).  The reference cells act as both an internal control and to ensure 
survival of the recipient animals.  Host and donor cells were distinguished using different 
alleles of the CD45 surface antigen, which is expressed on all haemopoietic cells except 
mature erythrocytes and platelets.  Specific antibodies were used against CD45.1 for the 
recipient, and against CD45.2 on the donor cells.  Recipient mice receiving such mixed donor 
transplantations provide a very sensitive way of comparing the behaviour and potency of wild 
type and knockout HSC.  Cell engraftment was determined by assessment of the proportion of 
test and reference donor cells in the peripheral blood at various time points following 
transplantation.  At three to six months post transplantation, the recipients were sacrificed.  
The bone marrow was extracted, analysed and 106 total bone marrow cells were transplanted 
into lethally irradiated BoyJ recipients.  Table 3.2 presents a summary of the sets of primary 
transplantations that were performed, displaying the number of donor wild type and nf!b1-/- 
mice (always littermates) and the number of recipients that were injected with each of the 
donor KSL populations.  The donor to reference (D:REF) ratios in the peripheral blood 
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samples are presented together with the equivalent ratio in the bone marrow at the end of the 
experiment when the recipients were sacrificed.   
3.8.1 Peripheral blood analysis 
Peripheral blood analysis of animals transplanted with nf!b1-/- KSL cells revealed two 
different phenotypes.  When peripheral blood was analysed at 4, 8, 12, and 16 weeks, half of 
the nf!b1-/- transplants did not exhibit reconstitution (nf!b1-/- non-engrafting), while the others 
showed good engraftment (nf!b1-/- engrafting).  Figure 3.11 represents an analysis of 
transplantations from Set 2.  The nf!b1-/- non-engrafted recipients all received KSL cells from 
the same knockout donor while the nf!b1-/- engrafted recipients all received KSL cells from 
another knockout littermate.  This result has been confirmed in three independent experiments 
using different donor and host mice (Table 3.2).  Furthermore, analysis of the different 
lineages revealed that transplanted KSL cells from nf!b1-/- mice were able to differentiate 
towards all B-, T- and myelomonocytic cells without any deficiency.  Hence, staining for 
markers of B-cells (B220/CD43), T-cells (CD4/CD8) and myelomonocytic cells (Gr1/CD11b) 
showed that there was no difference in the development of these lineages from the 
transplanted nf!b1-/- KSL cells compared to WT KSL cells (Figure 3.12).   
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Figure 3.11: Transplantation of wild type and nf!b1-/- KSL cells into lethally 
irradiated recipients. For competitive repopulation assays recipient mice (B6:SJL, 
CD45.1/CD45.1) were lethally irradiated (900 Gy) and injected via the tail vain with 
1x106 reference wild type ACK-treated whole bone marrow cells (B6XB6:SJL F1, 
CD45.1/CD45.2) together with 500 KSL donor cells from either wild type (WT) or 
nf!b1-/- (KO) mice (C57BL6/J, CD45.2/CD45.2). The figures show analysis of 
peripheral blood samples at 4, 8, 12 and 16 weeks following transplantation using anti-
CD45.1 and anti-CD45.2 to distinguish donor and reference cells. The schematic 
indicates the expected positions of the donor (CD45.2/CD45.2), reference (CD45.1/
CD45.2) and host (CD45.1/CD45.1) populations. !
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 3.8.2 Bone marrow analysis  
It is important to analyse the bone marrow of the primary recipients to evaluate the extent of 
engraftment and to assess the profile of the HSC compartment that develops following 
transplantation.  Thus, at 20 or 27 weeks post-transplantation, the primary recipients were 
sacrificed and their bone marrow was analysed.  Bone marrow cells were also used for 
transplantation into secondary irradiated recipient mice.   
To confirm that recipient mice transplanted with nf!b1-/- donor KSL cells revealed two 
different phenotypes in the bone marrow as seen in the peripheral blood, cells were stained 
with antibodies against CD45.1 and CD45.2.  As expected from the peripheral blood analyses, 
half of the nf!b1-/- transplants did not exhibit reconstitution (nf!b1-/- non-engrafting) while the 
others showed good engraftment (nf!b1-/- engrafting) in the bone marrow that was comparable 
to a wild type engraftment (Figure 3.13).  To assess if there was any comparison of the 
observed phenotypes in the adult nf!b1-/- mice to the recipients that were transplanted with 
nf!b1-/- KSL cells, an analysis of progenitor and KSL compartments was performed by 
immunofluorescent flow cytometry.  Analysis of the lineage negative fraction revealed a 
small increase in the mice receiving knockout cells compared to those transplanted with the 
wild type cells.  However, there were no significant differences in the progenitor populations 
(GMP, CMP and MEP) in the recipients receiving nf!b1-/- KSL cells compared to the wild 
type (Figure 3.14B), even though the adult bone marrow of the nf!b1-/- mice exhibited a 
significantly lower number of GMPs and CMPs and a significant increase in the MEP 
population (Figure 3.2).  Similar to the knockout donor mice, there was an increase in the 
KSL population amongst the donor population in the recipient animals, however this was not 
statistically significant.  Similar to the adult bone marrow (Figure 3.3), very small differences   
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Table 3.2: Primary transplantations of wild type versus nf!b1-/- bone marrow HSCs 
The table details the sets of transplantations performed.  The individual donors and recipients 
used in each set are indicated, as are the ratios of the donor to reference (D:REF) engrafted 
cells in the peripheral blood at various time points and when the bone marrow was eventually 
analysed.   
Ratio (D:REF) 
Set Mouse 
number 
CD45.2 
(Donor) 
KSL 
cells 
4 
weeks 
8 
weeks 
12 
weeks 
16 
weeks 
20 
weeks 
27 
weeks 
 
BM 
Analysis 
 13 WT1 0.45 1 1.2    1.45 
 14 WT2 0.33 0.68 1.04    1.2 
1 15 nf!b1-/- 1 0.02 0.01 0.05    0.1 
 16 nf!b1-/- 1 0.01 0.01 0.16    0.4 
 17 nf!b1-/- 2 0.04 0.07 0    0 
 19 nf!b1-/- 2 0.03 0.06 0.01    0 
 20 WT3 0.7 1.46 1.86 3.1  1.7 6 
 21 WT4 0.5 1.86 1.28 0.97  1 1.08 
 22 WT4 0.78 1.18 1.0 0.  82  1.1 1.9 
 23 nf!b1-/- 3 0.01 0 0 0  0 0 
2 24 nf!b1-/- 3 0 0 0 0  0 0 
 25 nf!b1-/-  4 0.48 0.16 0.3 0.58  0.3 0.5 
 26 nf!b1-/- 4 3.8 5.4 2.28 1.12  1.3 0.7 
 27 nf!b1-/-  4 0.79 2.2 2.9 2.25  1.6 1.29 
 30 WT5 0.24 0.29 1.86  0.93 1.7 6 
 31 WT6 0.28 0.87 1.28  2.79 1.93 1.08 
 32 WT6 0.17 0.42 1.0  0.37 1.1 1.9 
 33 nf!b1-/- 5 0 0 0  0 0 0 
3 34 nf!b1-/- 5 0 0 0  0 0 0 
 35 nf!b1-/- 5 0 0 0.3  0 0 0 
 36 nf!b1-/- 6 0.28 0.12 2.28  0.38 0.3 0.5 
 37 nf!b1-/- 6 0.3 0.98 2.9  0.9 1.3 0.7 
 38 nf!b1-/- 6 0.58 0.84 1.52  2.2 1.6 1.29 
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Figure 3.12: Analysis of lymphoid and myeloid lineages in the peripheral blood of 
engrafted recipients transplanted with wild type and nf!b1-/- sorted bone marrow KSL 
cells. At 12 weeks post transplantation peripheral blood samples were collected from 
recipient mice numbers 20 and 27. Following red cell lysis the samples were stained with 
antibodies against lymphoid- and myeloid-associated surface markers. Samples were gated on 
forward scatter (FSC) and side scatter (SSC) to select live cells and gated for host (CD45.1/
CD45.1), reference (CD45.1/CD45.2) and donor/test (CD45.2/CD45.2) populations. (A) B-
cell markers B220 and CD43. The schematic indicates the positions for pro- and pre-pro B 
cells, pre B cells and mature B cells. (B) T-cell markers CD4 and CD8a. The schematic 
indicates the expected positions for T-helper (TH) and T-cytotoxic (TC) cells. (C) 
Myelomonocytic cell markers Gr1 and CD11b. The schematic indicates the positions for 
immature blasts, monocytes and neutrophils.  
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Figure 3.13: Analysis of bone marrow cells from recipients transplanted with wild 
type and nf!b1-/- donor sorted KSL cells. Bone marrow was extracted and red cells 
lysed from femurs and tibias of primary recipients receiving 500 KLS cells either from 
wild type (WT) or nf!b1-/- (KO) mice at 20 weeks post-transplantation. The dot plots 
represent the engraftment of recipient mice numbers 21, 24 and 27. Bone marrow cells 
were analysed using anti-CD45.1 and anti-CD45.2 to distinguish between donor and 
reference cells.  
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were observed in the recipient animals in the proportion of MPP and ST-KSL populations in 
the nf!b1-/- compared to the wild type donor populations (Figure 3.15 C and D).  Donor nf!b1-
/- LT-KSL cells were lower compared to the donor wild type equivalent in the engrafted 
recipients (Figure 3.15A).  The side population of bone marrow HSCs was shown to be lower 
in nf!b1-/- compared to wild type mice (Figure 3.4).  To assess if this phenotype was 
maintained following transplantation of KSL cells, the side population was analysed.  This 
revealed that transplantation of nf!b1-/- KSL cells into the wild type environment of the 
recipients did not promote any adoption of the KSL side population phenotype (Figure 3.16); 
however, the decrease in the donor nf!b1-/- KSL side population was not statistically 
significant in comparison to that seen in the adult nf!b1-/- mice. 
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Figure 3.14: Immunofluorescence analysis of engrafted progenitor cells in primary 
recipient bone marrow. Bone marrow cells from primary transplanted recipients of wild 
type (WT:REF) and nfkb1-/- (KO:REF) mice were stained with a cocktail of antibodies 
against lineage associated surface markers (CD5, CD8a, CD11b, Gr1, Ter119 and B220). 
The histogram represents the average percentage of lineage negative cells from at least 4 
WT:REF and 4 KO:REF transplanted mice. The bars indicate the SEM. (B) Using the 
stem cell markers c-Kit and Sca-1 in combination with lineage negativity and CD16/32 
and CD34 antibodies the progenitor populations were analysed containing the 
granulocyte / monocyte progenitor (GMP), common myeloid progenitor (CMP) and 
megakaryocyte / erythroid progenitor (MEP). The histogram represents the average 
percentage of the different progenitor cell populations from WT:REF and KO:REF 
transplanted mice. The bars indicate the SEM. P>0.05 
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Figure 3.15: Immunofluorescence analysis of engrafted stem cells in primary recipient 
bone marrow. (A) The bone marrow from recipients of wild type (WT:REF) and nf!b1-/- 
(KO:REF) was stained with a cocktail of antibodies against lineage associated surface 
markers (CD5, CD8a, CD11b, Gr1, Ter119 and B220) and stem cell markers c-Kit and 
Sca-1. The histograms represents the average percentage of of donor (WT or KO) and 
reference (REF) KSL cells in transplanted mice. The bars indicate the SEM. (B) (C) and (D) 
KSL cells co-stained with Flt3 and CD34. The histograms represents the average percentage 
of donor (WT or KO) and reference (REF) LT-HSC, ST-HSC and MPP cells in transplanted 
mice. The bars show SEM (n=4) P>0.05 
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Figure 3.16: Analysis of bone marrow from wild type and nf!b1-/- primary 
recipients using the DNA binding dye Hoechst 33342. The bone marrow from 
recipients of wild type (WT:REF) and nf!b1-/- (KO:REF) was extracted, red cells 
lysed, then stained with Hoechst 33342 as previously described (Goodell et al, 
1996) and subsequently co-stained with a cocktail of antibodies against lineage-
specific surface markers (CD5, CD8a, CD11b, Gr1, Ter119 and B220) and stem cell 
markers c-Kit and Sca-1. The Hoechst 33342 profile analysis was performed 
following gating for forward scatter (FSC) versus side scatter (SSC), focussing on 
the lineage negative and KSL fractions. The histogram represents the average 
percentage of cells in the SP gate with bars indicating the SEM (n=3) P>0.05.  
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3.9 Secondary transplantation of nf!b1-/- bone marrow cells into lethally irradiated 
recipients 
The most precise way to test HSC potential is to assess their ability to be serially transplanted 
from the primary reconstituted recipients into a secondary lethally irradiated host, 
demonstrating that the engrafted cells are undergoing self-renewal.  Therefore, one million 
total bone marrow cells from primary recipients were transplanted into BoyJ (CD45.1) host 
mice.  These bone marrow cells were a mixture of either wild type (CD45.2/CD45.2) and 
reference cells (CD45.1/CD45.2) or nf!b1-/- and reference cells.  Peripheral blood samples 
were taken and analysed every 4 weeks to assess secondary engraftment using antibodies 
against CD45.1 and CD45.2.  Analysis of the peripheral blood of the secondary recipients 
revealed the presence of wild type and nf!b1-/- donor cells in the host mice (Figure 3.17).  The 
peripheral analysis at various time points of different recipients is presented in Figures 3.18, 
3.19, and 3.20 and a summary of all recipients is presented in Table 3.3. 
Analysis of the bone marrow of the secondary recipients proved problematic. Hence, using 
the surface markers CD45.1 and CD45.2 it was not possible to separate clearly donor or 
reference populations (See Appendix for further bone marrow analyses (Figure A5)).  For that 
reason, it was decided not to analyse further the bone marrow of the secondary transplanted 
recipients.  
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Figure 3.17: Immunofluorescence analysis of peripheral blood of secondary 
recipients of wild type and nf!b1-/- donor bone marrow cells. Peripheral 
blood samples were collected from secondary recipient mice numbers 51 and 59 
that had received 1 x 106 wild type (WT:REF primary) or nf!b1-/- (KO:REF 
primary) test cells from primary recipient mice. Following red cell lysis the 
samples were stained with antibodies against CD45.1 and CD45.2.  
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Figure 3.18: Immunofluorescence flow cytometry analysis of peripheral blood 
from secondary bone marrow transplant of WT:REF primary cells.  Peripheral 
blood samples were collected at different time points from recipient mouse 51 that had  
received 1 x 106 bone marrow cells from primary WT:REF recipient number 30 (see 
Table 3.3).  Following red cell lysis, the samples were stained with antibodies against 
CD45.1 and CD45.2 to distinguish between host (CD45.1/CD45.1), donor reference 
(REF) (CD45.1/CD45.2) and donor test (WT) (CD45.2/CD45.2) cells. 
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Figure 3.19: Immunofluorescence flow cytometry analysis of peripheral blood 
from secondary bone marrow transplant of KO:REF primary cells.  Peripheral 
blood samples were collected at different time points from recipient mouse 55 that had  
received 1 x 106 bone marrow cells from primary KO:REF recipient number 36 (see 
Table 3.3).  Following red cell lysis, the samples were stained with antibodies against 
CD45.1 and CD45.2 to distinguish between host (CD45.1/CD45.1), donor reference 
(REF) (CD45.1/CD45.2) and donor test (KO) (CD45.2/CD45.2) cells. 
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Figure 3.20: Immunofluorescence flow cytometry analysis of peripheral blood 
from secondary bone marrow transplant KO:REF primary cells.  Peripheral blood 
samples were collected at different time points from recipient mouse 60 that had  
received 1 x 106 bone marrow cells from primary KO:REF recipient number 38 (see 
Table 3.3).  Following red cell lysis, the samples were stained with antibodies against 
CD45.1 and CD45.2 to distinguish between host (CD45.1/CD45.1), donor reference 
(REF) (CD45.1/CD45.2) and donor test (KO) (CD45.2/CD45.2) cells. 
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Ratio 
(D:REF)   
Mouse 
number 
Recipients from 
primary 
transplantation 
1000000 cells 
4 week 8 week 12 week 
16  
week 
20 
week 
29 
week 
49 WT 30 (WT:Ref primary) 0.83 1.7 1.18 1.6 1.8 1.64 
51 WT 30 (WT:Ref primary) 2.22 1.1 1.5 1.2 1.2 0.93 
52 WT 32 (WT:Ref primary) 2.72 1 0.45 0.5 0.5 0.56 
53 WT 32 (WT:Ref primary) 1.31 0.35 0.5 0.24 0.4 0.44 
55 nf!b1
-/- 36 (KO:Ref 
primary) 0.2 0.5 0.3 0.3 0.3 0.33 
59 nf!b1
-/- 37 (KO:Ref 
primary) 6.75 12 2.6 1.6 1.3 4.56 
60 nf!b1
-/- 38 (KO:Ref 
primary) 8 16.5 21 8.3 6.5 77 
61 nf!b1
-/- 38 (KO:Ref 
primary) 6.2 2.5 2.6 1.5 2.4 1.1 
Table 3.3: Secondary transplantation: Donors were taken from primary transplantation Set 3.  
Number of donors and recipients used in the transplantation, ratio of the donor to reference 
cell engraftments (D:REF) in the peripheral blood at various time points. 
 
3.10 Discussion 
The main aim of this project was to examine the role of the two transcription factors NF-!B1 
and NF-!B2 in the maintenance and function of HSCs through analysis of the consequences 
of their individual ablation in genetically modified mice.  The hypothesis of the study was that 
alteration of the expression of NF-!B proteins can disturb the normal balance of HSC 
proliferation and survival resulting in aberrant HSC function.   
In order to investigate this hypothesis we first looked at the expression pattern of the NF-!B 
family members in an HSC cell line (HPC7) in comparison to primary murine HSCs (KSL 
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cells).  Interestingly all five members of the family tested were expressed in HSCs, although 
RelB was expressed at a very low level.  Based on the expression pattern, we decided to 
concentrate on the properties of HSCs in nf!b1-/- and nf!b2-/- mice, in both cases examining 
HSC quiescence, proliferation, and differentiation.  Most importantly, serial bone marrow 
transplantation assays were performed in order to assess the true stem cell characteristics of 
the identifiable HSCs.   
As a first step in characterising the knockout animals, haemopoietic cell populations in the 
bone marrow from nf!b1-/- mice were analysed by cell surface immunophenotyping, but this 
did not reveal any differences compared to wild type mice.  Likewise, assessment of the 
different HSC compartments in the nf!b1-/- revealed no obvious alterations in the proportion 
of the LT-HSC, ST-HSC or MPP populations; although a 7 to 9 fold increase in the total KSL 
population was seen which might be due to decrese in apoptosis as the BrdU incorporation 
assay did not show any increase in proliferation.  Analysis of the various myeloid progenitor 
compartments showed a significant decrease in the GMP and CMP populations and a 
significant increase in the MEP population.  It has already been described that p50/p65 
complex is essential for lymphopoiesis, whereas normal myeloid cells can develop in 
presence of either p65 or c-Rel containing complexes, in this case showing a potential of 
compensation (Liou, 2002).  Thus, the significant increase in the nf!b1-/- MEP population 
might have resulted from compensation of NF-!B1 activity by other NF-!B members as we 
see in KSL cells (Figure 3.10).  
The assessment of side population numbers within the KSL HSC compartment showed a 
significant decrease of nf!b1-/- cells within this fraction, and for that reason we decided to 
study the cell cycle status of wild type and nf!b1-/- HSCs in order to gain some understanding 
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about their proliferation capacity.  But as mentioned before labelling of replicating cells by 
incorporation of BrdU revealed no significant differences between wild type and nf!b1-/- 
HSCs.   
Since, bone marrow cells displaying side population characteristics have been shown to have 
the capability of long term repopulation in lethally irradiated recipients, we performed both in 
vitro serial replating assays and in vivo transplantations to study the self-renewing capacity of 
nf!b1-/- HSCs.  
The replating assay of nf!b1-/- KSL cells showed a significant decrease in the number of 
colonies and changes in the colony sizes after the second round of replating and the large 
number of disperse differentiated cells over the plates after the third round.  This suggests that 
the nf!b1-/- KSL cells have significantly reduced self renewal capacity compared to the wild 
type cells. 
When tested by transplantation in vivo, the nf!b1-/- KSL cells exhibited two different patterns 
of engraftment.  Thus, half of the transplantations showed no repopulation while the others 
repopulated efficiently, at a similar level to that seen for wild type cells.  Given that the 
engraftments of knockout cells that failed corresponded to specific donor animals and that in 
these cases no engraftment was seen even at early time points, coupled with the fact that 
secondary transplantations always succeeded from those animals that had successfully 
engrafted with knockout cells suggests that the explanation lies in immune rejection.  The 
donor mouse population had been extensively backcrossed to a C57BL6 background (at least 
8 generations), so it seems reasonable to conclude that a rejection antigen is closely linked to 
the nf!b1 locus.  Another reason that might cause that half of the nf!b1 donor cells are not 
transplanting is their sensitivity to the FACS machine.  With other words cells might die 
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during the sorting procedure. If any of these explanations are correct, then the fact that half of 
the engraftments of knockout cells were very similar to those achieved with wild type cells 
implies that nf!b1-/- HSCs are functionally unaffected at this level.  
  
82 
 
 
CHAPTER 4 
ANALYSIS OF THE ROLE OF NF-!B2 IN HAEMOPOIETIC 
STEM CELLS 
4.1 Introduction 
A recent studyng using RelB/NF-!B2 double knockout mice has shown the involvement of 
the non-canonical NF-!B signalling pathway in the regulation of haemaopoietic stem and 
progenitor cell (HSPC) self-renewal, expansion and lineage commitment through an influence 
on the bone marrow microenvironment (Zhao et al., 2012).  The aim of the work described in 
this chapter was to investigate the function of NF-!B2 in HSC using single knockout mice.  
The analysis of RNA levels in HSCs described in Chapter 3 show that the NF-!B2 gene is 
expressed.  To determine the importance of NF-!B2 activity in HSCs we performed a parallel 
set of experiments to those described in Chapter 3 for NF- !B1. 
 
4.2 Comparison of haemopoietic cells in the bone marrow of wild type and nfkb2-/- mice 
To increase our understanding about the importance of the transcription factor NF-!B2 within 
the haemopoietic cell types constituting the haemopoietic hierarchy, the bone marrow of 
nf!b2-/- mice was extensively characterised in comparison to that from wild type littermates.  
Flow cytometry using the antibodies against B220/CD43 and CD4/CD8a revealed no 
differences in the number of lymphoid cells, and similarly analysis of myeloid populations, 
83 
 
identified with antibodies against CD11b/Gr1 and c-Kit/CD41, did not show any change 
comparing knockout mice to wild type (Table 4.1and see Appendix Figure A3 and A4). 
 
Cell type Surface markers Wild type versus nf!b2 knockout 
Lymphoid 
B220/CD43 (B-cells) 
CD4/CD8 (T-cells) 
Equivalent 
Myelomonocytic CD11b/Gr1 Equivalent 
Erythroid TER119/CD71/c-Kit Equivalent 
Megakaryocytic c-Kit/CD41 Equivalent 
Table 4.1: Immunofluorescent analysis of bone marrow cells from wild type versus 
nf!b2-/- mice.  Bone marrow was flushed from the femur and tibias of mice aged 8-10 weeks.  
The table represents different surface markers that were used to study the different 
haemopoietic lineages. (n=6) 
 
4.3 Analysis of the haemopoietic stem cell and progenitor compartments in wild type 
and nfkb2-/- mice 
The fact that there is no difference in the number of different mature haemopoietic cells 
comparing wild type and knockout bone marrow does not necessarily mean that there is no 
difference in the progenitor and stem cell compartments.  Therefore, the HSC compartments 
within the bone marrow of wild type and nf!b2-/- mice were analysed using a cocktail of 
antibodies against lineage-associated markers combined with antibodies against c-Kit and 
stem cell antigen Sca-1. The KSL compartment defined by this staining strategy was further 
subdivided into LT-KSL, ST-KSL and MPP using antibodies against CD34 and Flt3.  The 
GMP, CMP and MEP committed progenitor populations were also analysed using an 
antibody against CD34 in combination with anti-CD16/32 (Fc&RII/III).  This latter analysis 
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revealed no differences in the number of progenitors between wild type and knockout mice 
(data not shown).   
Staining with lineage markers revealed a statistically significant reduction in the proportion of 
lineage negative cells in the bone marrow of nf!b2-/- mice compared to the wild type 
littermates (Figure 4.1A).  Despite this, within lineage negative cells the proportions of Lin-c-
Kit+Sca-1- and KSL populations were similar in nf!b2-/- and wild type mice (Figure 4.1B).  
However, sub-fractioning the KSL compartment by co-staining with antibodies against CD34 
and Flt3 showed that there was a significant increase in the ST-HSC population and a 
significant decrease in the MPP population of nf!b2-/- mice compared to wild type.  The LT-
HSC population had very similar proportions between wild type and knockout animals 
(Figure 4.2). 
 
4.4 Analysis of wild type versus nf!b2-/- KSL cells using a phenotypic assay of stem cells 
As mentioned above, efflux of the DNA binding dye Hoechst is another way to characterise 
HSCs in murine bone marrow (Goodell et al., 1997),  and this assay was used to evaluate the 
HSCs of nf!b2-/- mice.  The bone marrow was extracted and treated to lyse red blood cells, 
then co-stained with Hoechst 33342 and antibodies to define the KSL population (Goodell et 
al., 1997).  Forward scatter (FSC) and side scatter (SSC) were used to gate live cells.  KSL 
cells from wild type and nf!b2-/- were gated and the distribution of the cells within the side 
population gate was assessed.  This analysis showed a lower percentage of side population 
cells in the knockout KSL population.  However, analysing several mice revealed that this  
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Figure 4.1: Immunofluorescence analysis of stem cell and progenitor populations in 
wild type and nf!b2-/- mice. The bone marrow from wild type (WT) and nf!b2-/- (KO) 
mice was extracted and the red cells lysed. Bone marrow cells were stained with a range 
of antibodies against lineage-committed markers (CD5, CD8a, CD11b, Gr1, Ter119 and 
B220). (A) Two-dimensional dot plots following gating of forward scatter (FSC) and side 
scatter (SSC) for live cells. The indicated gates represent the lineage negative fraction 
with the percentage of cells indicated. The histogram represents the average percentage of 
lineage negative cells from assessment of 4 WT and 4 KO mice. The bars indicate the 
SEM. (B) Two-dimensional dot plots showing the expression of Sca-1 and c-Kit in the 
gated lineage negative fraction. The R7 gate represents the progenitor population while R3 
represents the KSL population. The histograms represent the average percentage of 
progenitor (upper) and KSL (lower) cells from least 4 WT and 4 KO mice. The bars 
indicate the SEM (n=5) P>0.05 
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Figure 4.2: Immunofluorescence analysis of stem cell and progenitor populations in 
wild type and nf!b2-/- mice. Bone marrow from wild type (WT) and nf!b2-/- (KO) mice 
was extracted and the red cells were lysed. WT and KO bone marrow cells were stained 
with antibodies to define the KSL population. (A) Two-dimensional dot plots of gated 
KSL cells co-stained with antibodies against Flt3 (CD135) and CD34. The gates define the 
long-term HSC (LT-HSC: Flt3-CD34-), short-term HSC (ST-HSC: Flt3-CD34+) and 
multipotential progenitor (MPP: Flt3+CD34+) cells. (B) The histograms represents the 
average percentage of cells within each gate. The bars show SEM (n=4). * indicates 
significance (P<0.05) 
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Figure 4.3: Analysis of bone marrow from wild type and nf!b2-/- mice using the DNA 
binding dye Hoechst 33342. (A) The bone marrow of wild type (WT) and nf!b2-/- (KO) 
mice of 8-10 weeks of age was extracted and the red cells lysed. Cells were then stained 
with Hoechst 33342 as previously described (Goodell et al., 1997) and subsequently co-
stained with a cocktail of antibodies against lineage-specific surface markers (CD5, 
CD8a, CD11b, Gr1, Ter119 and B220) and the stem cell markers c-Kit and Sca-1. The 
Hoechst 33342 profile analysis was performed following gating for forward scatter (FSC) 
versus side scatter (SSC), focussing on the lineage negative and KSL fractions. The 
schematic indicates the position of the side population (SP) and the major population 
(MP). (B) The histogram represents the average percentage of cells in the SP and the MP 
gate with bars indicating the SEM (n=4) P>0.05. !
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change was statistically not significant.  The main population showed a very small change 
between wild type and knockout KSL cells (Figure 4.3).  
 
4.5 Comparative analysis of properties of wild type and nf!b2-/- bone marrow HSCs  
4.5.1 Cell cycle analysis of wild type and nf!b2-/- bone marrow haemopoietic stem cells    
To study the cell cycle status and proliferation capacity of the nf!b2-/- KSL cells, BrdU 
incorporation assays were performed in vitro and in vivo as described above, using confocal 
microscopy to analyse the data.  The in vitro BrdU incorporation assay (Figure 4.4A) showed 
a smaller percentage of BrdU-positive nf!b2-/- KSL cells compared to the wild type; however, 
this decrease is not statistically significant.  Similarly, the in vivo BrdU incorporation assay 
demonstrated a decrease in the percentage of BrdU-positive nf!b2-/- KSL cells compared to 
the wild type, which was also not statistically significant (Figure 4.4B).   
4.5.2 Colony forming potential 
To evaluate the proliferation and differentiation potential of the nf!b2-/- HSCs in vitro, colony 
assays were performed using sorted KSL cells.  350 KSL cells from wild type or nf!b2-/- mice 
were plated in methylcellulose.  The first plating showed a statistically significant higher 
number of colonies derived from nf!b2-/- KSL cells compared to the wild type.  Nevertheless, 
there were no changes observed in the types of colonies produced (Figure 4.5A).  For 
secondary replating, all cells from previous plates were collected, and 5000 cells were re-
seeded in fresh methylcellulose.  Upon secondary replating the capacity of the nf!b2-/- cells to 
form colonies was decreased relative to the wild type cells; although this was not significant 
(Figure 4.5B).  There was no difference in the size or morphology of colonies produced by the 
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nf!b2-/- cells compared to the wild type.  Upon tertiary replating, nf!b2-/- cells were hardly 
able to form colonies while the wild type cells retained their clonogenic potential and formed 
colonies (Figure 4.5C).  This result may suggest that nf!b2-/- KSL cells have diminished self-
renewal capacity in vitro.  
Another explanation for that could be that in the nf!b2-/- plate were more differentiated cells, 
which upon replating were not able to self-renew while in the wild type plates there were 
more immature cells which were able to form colonies. 
 
4.6 RNA analysis 
As for nf!b1-/- KSL cells (Figure 3.10), a gene expression profiling was also performed on 
sorted nf!b2-/- KSL cells to compare the expression of NF-!B family genes in the knockout 
with wild type cells.  Real-time PCR was performed for the NF-!B family member genes that 
are expressed in HSCs, using normalisation against HPRT.  As deletion of transcription factor 
NF-!B2 in KSL cells showed only a modest phenotype, it was speculated that this 
transcription factor might be compensated by other members of the family within KSL cells.  
In fact the RT-PCR analysis revealed that nf!b2 gene deletion resulted in increased nf!b1 
expression by up to 4.5-fold and rel-A expression by up to 4 fold in KSL cells (Figure 4.6).  
No difference could be seen in the expression of c-rel comparing wild type and nf!b2-/-. 
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Figure 4.4: Analysis of the proliferation of HSCs from wild type and nf!b2-/- mice. 
(A) Bone marrow cells from wild type (WT) and nf!b2-/-  (KO) mice at 8-10 weeks of 
age was extracted and the red cells lysed. KSL cells were sorted and placed in a liquid 
culture for 12 hours in IMDM containing BrdU. After labelling, the cells were collected, 
fixed and denatured. After blocking, the cells were incubated overnight with the primary 
monoclonal rat anti-BrdU antibody. One day later the cells were washed and fixed with 
paraformaldehyde and quenched with NH4Cl and finally incubated for 2 hours with 
AlexaFluor 488 donkey anti-rat. The cells were mounted with DAPI-containing 
Vectashield and images were acquired using the Zeiss LSM 510 Meta confocal 
fluorescence microscope. (B) For in vivo BrdU incorporation assay, mice were injected 
intra-peritoneally with BrdU and sacrificed after 24 hours. Bone marrow cells were 
sorted for KSL cells, and stained as described in (A) (n=4) P>0.05  
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Figure 4.5: Analysis of the colony forming potential of wild type and nf!b2-/- KSL cells. 
350 sorted KSL cells from wild type (WT) and nf!b2-/- (KO) mice were plated in semisolid 
methylcellulose medium (Methocult M3434) supplemented with TPO. (A) Histograms 
showing the number and morphology of colonies after 7 days. The pictures illustrate the 
morphology of CFU-GM and CFU-G colonies. Secondary (B) and tertiary (C) replating of 
5000 cells was performed using cells collected from previous plates. The number of colonies 
and the total number of cells were assessed after 7 days. All cultures were incubated at 37°C in 
a fully humidified 5% CO2 in air atmosphere (n=5) * indicates significance (P<0.05) 
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Figure 4.6: Expression of NF-!B family genes in wild type versus nf!b2-/- KSL 
cells. RNA was extracted from KSL cells from the bone marrow of wild type and 
nf!b2-/- mice and converted into cDNA. Real time PCR was then performed on the 
cDNA using SYBR Green and primers specific for the nf-!b family members. The 
cDNA was normalised using the HPRT gene as a control. The figure represents results 
obtained from two experiments and shows the abundance in nf-kb2 knockout cells 
relative to the wild type. Each PCR was performed in triplicate and the error bars 
represent the SEM.  
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4.7 Assessment of nf!b2-/- HSC function by transplantation into lethally irradiated 
recipients 
To assess the function and potency of nf!b2-/- HSC in vivo, serial transplantation assays were 
performed into lethally irradiated recipient mice as described before in Chapter 3.   
After transplantation of 500 nf!b2-/- or wild type KSL cells into recipient mice, together with 
106 whole bone marrow reference cells, peripheral blood samples were taken at different time 
points to assess the relative engraftment of donor and reference cells.  Table 4.2 summarises 
the number of sets of transplantations that have been done during the project and details the 
individual donor wild type and nf!b2-/- mice (always littermates) and the recipients that have 
been injected with donor KSL cells. Set 2 transplanations did not show any engraftment, 
either of wild type or knockout cells, and for this reason these transplantations are not 
presented. For each transplanted animal, the ratios of donor to reference cells in the peripheral 
blood and bone marrow of recipients were calculated (Table 4.2) as described in Sections 
4.7.1 and 4.7.2. 
4.7.1 Peripheral blood analysis 
Peripheral blood as taken from recipient animals at several stages following transplantation, 
and the donor and reference haemopoietic cells were distinguished by flow cytometry after 
staining with antibodies against CD45.1 and CD45.2.  This analysis showed that recipients 
receiving KSL cells from a given nf!b2-/- donor mouse gave rise to two different 
transplantation phenotypes.  Cells either did not engraft (nf!b2-/- non-engrafted) or engrafted 
efficiently, both in the short and long term, and had a competitive advantage relative to the 
reference cells (nf!b2-/- engrafted).  Figure 4.7 illustrates an example of engraftments in 
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recipients 101, 112 and 108 taken from Set 1 transplantations.  The efficiency of engraftment 
with nf!b2-/- donor KSL cells was only 25 to 33.3%, despite the nf!b2-/- engrafted mice 
showing an over-proliferation and a competitive advantage of the donor cells.  The remaining 
nf!b2-/- recipients showed no engraftment of donor cells, even though KSL cells from the 
same knockout mouse were able to engraft in other recipients.  In complete contrast, KSL 
donor cells from wild type animals showed consistent engraftment, with virtually all of the 
recipient mice showing evidence of transplant engraftment (Table 4.2). 
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Table 4.2 Primary transplantation of wild type versus nf!b2-/- bone marrow HSCs. The 
table details the sets of transplantations performed. The individual donors and recipients used 
in each set are indicated, as are the ratios of the Donor: Reference (D:REF) engrafted cells in 
the peripheral blood at various time points and when the bone marrow was eventually 
analysed. 
 
Ratio (D:REF)   
Set Mouse 
number 
CD45.2 
(Donor) 
KSL cells 
4 
weeks 
8 
weeks 
12 
weeks 
16 
weeks 
17 
weeks 
19 
weeks 
 
20 
weeks 
BM 
analysis 
 101 WT1 0.29 0.3  0.47   0.34    1.23 
 102 WT1 0.22 0.48  0.51   0.07    0.24 
 103 WT2  0.08 0.42  0.38  0.  35    0.39 
 104 nf!b2-/- 1 0 0.01  0.02  0.01    0.01 
 105 nf!b2-/- 1 0.08 0.04  0.04   0.01    0.03 
1 106 nf!b2-/- 1 0.3 0.07  0.005   0.01   0.002 
 107 nf!b2-/- 1 0.47 3.92  11.5   3    14.4 
 108 nf!b2-/- 2 4.8 5.7  4.6   2.8    18.85 
 109 nf!b2-/- 2 0.19 0.1 0.09   0.03    0.03 
 110 nf!b2-/- 2 1.25 0.01 0.02   0.01    0.005 
 111 nf!b2-/- 2 0.29  0.37  1.96   1.16    7 
 112 nf!b2-/- 2 0.02  0.005 0.01   0.004    0.001 
 82 WT5 0.07  0.2  0.3  0.4   0.4 1.5  
 83 WT5 0.2  0.7  0.5  0.5   0.5  5.2 
 84 WT5 0.15  0.36  0.5  0.67   0.61  1.04 
 85 WT5  0.06 0.19  0.48  0.7   ------ 1.25 
 86 WT5  0.10 0.32  0.56  0.79   0.68  0.83 
 87 WT6  0.01  0.56  1.25  1.93   2.5 2.2 
3 88 WT6  0.14  0.08  0.05  0   0.06  0.3 
 89 nf!b2-/- 5  0.006  0  0  0   0  0.3 
 90 nf!b2-/- 5  0.03  0.01 0.02  0   0 0.4 
 91 nf!b2-/- 5 0.04  0.19  1.07  1   0.86  10.5 
 92 nf!b2-/- 5  0.05  0.02  0.12  0.16   0.14  0.3 
 93 nf!b2-/- 6  0.04  0.27  0.58  0.8   0.69 9.2 
 94 nf!b2-/- 6  0.08  0  0  0   0 0.09 
 95 nf!b2-/- 6  0.03  0.01  0.01  0.01   0.01  0.2 
 96 nf!b2-/- 6 0  0  0  0   0  0.4 
 97 nf!b2-/- 6 0  0  0.02  0.01   0.01  0.3 
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Immunofluorescence flow cytometry of the peripheral blood of engrafted nf!b2-/- engrafted 
recipients following staining with antibodies specific for the B-cell lineage (CD43/B220) 
revealed that transplanted nf!b2-/- KSL cells had a deficiency in B-cell development, showing 
up to 50% reduction of mature B cells compared to control wild type transplanted KSL cells 
or the reference cells (Figure 4.8A).  In contrast, staining for markers against T-cells 
(CD4/CD8) showed no change in the development of this population arising from the nf!b2-/- 
KSL donor cells (Figure 4.8B).  However, recipient mice engrafted with nf!b2-/- cells 
exhibited a 4- to 5-fold increase in myeloid populations with CD11b+Gr1- and CD11b+Gr1+ 
phenotypes, when compared to transplanted wild type KSL cells or reference cells (Figure 
4.8C).  These findings were unexpected, as previous analyses of nf!b2-/- mice showed no 
decrease in mature B-cell development or any increase in myeloid populations (Section 4.2).  
The changes in the nf!b2-/- lineage development therefore revealed only upon transplantation.   
After seeing the changes in B-cell and myeloid cell development of nf!b2-/- engrafted cells in 
the peripheral blood, it was necessary to investigate if there were any other phenotypic 
changes in the blood of the recipient animals.  Therefore, on the day of sacrifice, cardiac 
punctures were performed and blood counts were obtained.  On average there were no 
significant changes in the white blood cell (WBC) and red blood cell (RBC) counts or the 
haemoglobin (HGB) levels, but there was a statistically significant increase in the platelet 
value, which is shown in the Appendix (Figure A6). 
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Figure 4.7: Transplantation of wild type and nf!b2-/- KSL cells into lethally irradiated 
recipients. For competitive repopulation assays recipient mice (B6:SJL, CD45.1/CD45.1) 
were lethally irradiated (900 Gy) and injected via the tail vain with 1x106 reference wild type 
ACK-treated whole bone marrow cells (B6XB6:SJL F1, CD45.1/CD45.2) together with 500 
KSL donor cells from either wild type (WT) or nf!b2-/- (KO) mice (C57BL6/J, CD45.2/
CD45.2). The figures show analysis of peripheral blood samples at 4, 8, 12 and 17 weeks 
following transplantation and eventually when the bone marrow (BM) was analysed using 
anti-CD45.1 and anti-CD45.2 to distinguish donor and reference cells. These dot plots are 
representing the peripheral blood analysis of three recipient mice (101, 112 and 108) at 
different time points taken from transplantation Set 1. !
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Figure 4.8: Analysis of lymphoid and myeloid lineages in the peripheral blood of 
engrafted recipients transplanted with wild type and nf!b2-/- KSL cells. At 12 weeks post 
transplantation peripheral blood samples were collected from recipient mice number 101 and 
108 that received wild type or nf!b2-/- KSL cells. Following red cell lysis the samples were 
stained with antibodies against lymphoid- and myeloid-associated surface markers. For live 
cells, samples were gated on forward scatter (FSC) and side scatter (SSC), and for host 
(CD45.1/CD45.1), reference (CD45.1/CD45.2) and donor (CD45.2/CD45.2) populations. (A) 
B-cell markers B220 and CD43. (B) T-cell markers CD4 and CD8a. (C) Myelomonocytic cell 
markers Gr1 and CD11b. !
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4.7.2 Bone marrow analysis 
At approximately six months post-transplantation, the recipients of the primary nf!b2-/- and 
wild type donor KSL cells were sacrificed and their bone marrow was analysed to assess 
engraftment of the donor and reference cells.  Bone marrow cells were also used for 
secondary transplantation into lethally irradiated mice. 
To determine whether recipient mice transplanted with nf!b2-/- donor KSL cells exhibited two 
different phenotypes in the bone marrow, as seen previously in the peripheral blood, cells 
were stained with antibodies against CD45.1 and CD45.2.  In general, individual recipients 
that showed no engraftment of nf!b2-/- KSL cells in the peripheral blood also showed no 
engraftment of donor cells in the bone marrow (Table 4.2).  Similar to the peripheral blood 
analysis, the 25 to 33% of the nf!b2-/- engrafted recipients showed an over-proliferation and a 
competitive advantage of these donor cells in the bone marrow compared to the reference 
population.   
The previous analysis of the bone marrow HSC in nf!b2-/- mice showed a significantly lower 
number of lineage negative cells compared to the wild type (Section 4.3).  In addition, sub-
fractionation of the nf!b2-/- KSL cells revealed an increase in the ST-HSC and a decrease in 
the MPP population compared to the wild type, whereas no difference was observed in the 
LT-HSC sub-fraction (Section 4.3).  To evaluate whether these differences in the 
progenitor/stem cell compartments is also be found in the bone marrow following 
transplantation, an analysis of progenitor and KSL compartments was performed using 
appropriate antibodies by immunofluorescence flow cytometry.  Analysis of the lineage 
negative fraction revealed no differences between nf!b2-/- or wild type engrafted cells in the  
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Figure 4.9: Analysis of bone marrow cells from recipients transplanted with wild type 
and nf!b2-/- test donor sorted KSL cells. Bone marrow was extracted from femurs and 
tibias of primary recipients receiving 500 KSL cells from either wild type (WT) or nf!b2-/- 
(KO) mice at approximately 17 weeks  post-transplantation. Bone marrow samples were 
lysed to remove red cells and analysed using anti-CD45.1 and anti-CD45.2 to distinguish 
between donor and reference cells. The dot plots represent the engraftment of recipient 
mice 101, 108 and 112.  
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Figure 4.10: Immunofluorescence analysis of engrafted progenitor cells in primary 
recipient bone marrow. Bone marrow from primary transplanted recipients of wild 
type (WT:REF) and nfkb2-/- (KO:REF) mice were stained with a cocktail of antibodies 
against lineage associated surface markers which consisted (CD5, CD8a, CD11b, Gr1, 
Ter119 and B220). (A) The histograms represents the average percentage of lineage 
negative cells from 4 WT:REF and 5 KO:REF mice. The bars indicate the SEM. (B) 
Using the stem cell markers c-Kit and Sca-1 in combination with lineage negative 
surface markers the progenitor population was analysed. The histograms represents the 
average percentage of the progenitor cell populations from 4 WT:REF and 5 KO:REF 
mice. The bars indicate the SEM P>0.05 !
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Figure 4.11: Immunofluorescence analysis of stem cell compartments of wild type and 
nf!b2-/- mice. The bone marrow cells from recipients of wild type (WT:REF) and nf!b2-/- 
(KO:REF) mice were were stained with a cocktail of antibodies against lineage associated 
surface markers (CD5, CD8a, CD11b, Gr1, Ter119 and B220) and stem cell markers c-Kit 
and Sca-1. (A) The histogram represents the average percentage of KSL cells from WT:REF 
and KO:REF mice. The bars indicate the SEM. (B) (C) and (D) KSL cells co-stained with 
Flt3 and CD34. The histograms represents the average percentage of donor (WT or KO) and 
reference (REF) LT-HSC, ST-HSC and MPP cells in transplanted mice. The bars show SEM 
P>0.05!
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bone marrow of recipient mice (Figure 4.10 A), which contrasts with the findings in non-
transplanted knockout mice (Figure 4.1A).  Whereas non-transplanted nf!b2-/- and wild type 
mice had similar progenitor (Lin-Sca1-c-Kit+) populations, the progenitor cells derived from 
nf!b2-/- grafts were decreased in comparison to the wild type grafts (Figure 4.10B).  However, 
within the progenitor population of nf!b2-/- engrafted cells, there were no evident differences 
compared to wild type in the GMP, CMP and MEP sub-populations (data not shown).  As 
with non-transplanted nf!b2-/- mice, nf!b2-/- grafts showed hardly any differences compared to 
wild type in the proportion of KSL cells in the bone marrow of the recipients mice following 
transplantation (Figure 4.11A).  Within this KSL compartment, ST-HSC cells were slightly 
increased in nf!b2-/- grafts (Figure 4.11C).  Although this was superficially similar to the 
observation in non-transplanted nf!b2-/- mice (Section 4.3), the increase in the ST-HSC sub-
fraction in nf!b2-/- grafts was not statistically significant (Figure 4.11C).  The LT- HSC sub-
fraction was similar in nf!b2-/- and wild type grafts (Figure 4.11B), as seen in non-
transplanted mice (Section 4.3).  Whereas a significant decrease in MPP cells was observed in 
non-transplanted nf!b2-/- mice compared to wild type, this difference was not detected in 
grafts (Figure 4.11 D).   
 
4.8 Discussion 
The NF-!B2 transcription factor is part of the non-canonical pathway that is suggested to 
regulate important biological functions, such as lymphoid organogenesis and B-cell survival 
and maturation.  The function of this transcription factor in HSCs has not been described 
before. 
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As in the nf!b1-/- mice, nf!b2-/- mice did not demonstrate any differences in the number of 
different haemopoietic cells when wild type and knockout bone marrow were compared.  
Interestingly, the nf!b2-/- mice exhibited a statistically significant increase in the ST-HSC 
compartments and a significant decrease in the MPP population (Figure 4.2), reflecting the 
results obtained from the BrdU incorporation assays (Figure 4.4). The increase in ST-HSC 
compartment miht be due to the fact that this population is more proliferative. However this 
need to be further tested by e.g performing BrdU incorporation assay on KSL subpopulations, 
or by pyroninY staining, or Ki67 staining. Furthermore the decrease in MPP population might 
be du to the fact that there might be a blockage in the differentaion stage, thus when ST-HSCs 
differentiate into MPP cells.  
The serial replating assay of nf!b2-/- KSL cells showed that these cells were not able to form 
colonies compared to the wild type cells after three cycles of replating, indicating that they 
have lost their in vitro potential for self-renewal. 
Transplantation of the nf!b2-/- KSL cells into lethally irradiated recipients also gave two 
distinct outcomes; however, unlike the situation seen for the nf!b1-/- transplantations in which 
a co-segregating transplantation antigen appeared to be responsible for the two transplantation 
behaviours, in the case of the nf!b2-/- donors, KSL cells from the same donor knockout mouse 
yielded both phenotypes, that is, no engraftment or engraftment with an increased 
proliferation phenotype and a competitive advantage.   
The recipients that showed a proliferation phenotype also exhibited an increase in 
myelomonocytic cells in the peripheral blood, and a decrease in CD43-B220+ cells, indicating 
a blockage in B-cell development (B220+ cells include pre-B and mature B-cells) but normal 
T-cell development.  The increase in CD11b+Gr1+ cells in the peripheral blood might be the 
105 
 
result of extramedullary haemopoiesis.  NF-!B activity is necessary for the development of B-
cells and their survival at various developmental stages (Claudio et al., 2009).  Hence, it has 
already been shown that nf!b2-/- mice have abnormalities in the splenic architecture, lymph 
nodes and Peyer’s patches and show a reduction in the B-cell compartments (Caamano et al., 
1998).  However, another study performed by Claudio and colleagues demonstrated that 
nf!b1/nf!b2 double knockout mice show a partial reduction in late pre-B and immature B-
cells populations (CD43-B220+).  This encompasses the later B-cell developmental stage in 
the bone marrow, suggesting that NF-!B1 and NF-!B2 promote B-cell development during 
transit through the late pre-B and immature stages (Claudio et al., 2009).   
In the case of those recipients that did not exhibit engraftment, an immunological mismatch is 
not a credible explanation as KSL cells from a single knockout donor mouse exhibited the 
two different phenotypes.  These results therefore suggest that the absence of NF-!B2 leads 
directly to a change in proliferation/self-renewal potential, the precise outcome of which in a 
transplantation assay depends on yet to be determined factors.   
One possibility why the nf!b2-/- KSL cells did not repopulate in some animals is that 
migration or homing processes might be affected.  Usually when transplanting cells 
intravenously into the tail vein the cells home from the peripheral circulation to the vascular 
niche, undergoing transendothelial migration and finally entering the osteoblastic niche 
(Lapidot et al., 2005).  After homing to the bone marrow and settling in the niche, HSCs have 
to go through several steps to achieve successful long-term engraftment including 
proliferation and differentiation into all blood cell types (Adams et al., 2007).  By perforning 
intrafemular injection of the KO cells we would be able to assess if the cells are having defect 
in their homing upon transplantation.  The HSC niche has been shown to play an important 
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role in the maintenance of stem cell function.  Thus there are different gene products involved 
in the HSC and niche interaction.  Several chemokines and signalling and adhesive molecules 
are involved in HSC mobilisation and homing.  NF-!B activity is induced by over 150 
different proteins and in turn is involved in the transcription of over 150 target genes (Pahl, 
1999), so that it could potentially influence many of the molecules that that are involved in 
HSC mobilisation and homing.  It has already been shown that some genes that are involved 
in HSC function and niche interaction are NF-!B target genes in other cell types, such as SCF 
and angiopoietin-1/Tie2 (Da Silva and Frossard, 2005, Scott et al., 2005). Another future 
experiment that could give us an idea about the bone marrow microenvironment of the KO 
mice would be transplanting wild type bone marrow KSL cells into KO mice. This would 
show if the KO KSL cells are having an autonomous or a non-autonomous effect.  
The results of the secondary transplantations performed in the case of assessment of the effect 
of the nf!b2 knockout were difficult to interpret as these had been obtained from Set 2 
primary transplantations that showed very little engraftment of either wild type or knockout 
KSL cells. This was most likely due to technical issues such as problems with the irradiation 
of the recipient.  Due to time restrictions it was not possible to repeat the secondary 
transplantations. 
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CHAPTER 5 
DISCUSSION 
As detailed in Chapter 1, NF-!B activity has been implicated in HSC and LSC survival and 
development.  Several studies have shown that there is constitutive NF-!B activity in 
haemopoietic cancers including acute myeloid leukaemia (AML), acute lymphoblastic 
leukaemia (ALL), chronic lymphocytic leukaemia (CLL), and multiple myeloma (MM).  
Guzman and colleagues were the first to observe constitutive activation of NF-!B 
transcription factor activity in primary AML LSCs, and this is thought to be associated with 
anti-apoptotic activity of the NF-!B proteins that leads to the survival of these cells (Guzman 
et al., 2001, Wang et al., 1996, Wang et al., 1998).  In addition, the same group has shown 
that treatment of LSCs with a combination of anthracycline idarubicin and the proteasome 
inhibitor MG-132, which prevents NF-!B activation, induces a very rapid onset of apoptosis 
in LSCs, supporting the view that NF-!B is involved in LSC survival (Guzman et al., 2002).  
The expression of NF-!B has also been shown in primitive umbilical cord blood CD34+ HSCs 
(Panepucci et al., 2007), and only recently Zhao and colleagues showed the importance of the 
NF-!B non-canonical signalling pathway in haemopoietic stem/progenitor populations (Zhao 
et al., 2012).  In the latter study it was shown that relb/nfkb2 double-knockout (dKO) HSPCs 
had impaired engraftment and self-renewal activity upon transplantation into lethally 
irradiated recipient mice.  The relb/nfkb2 dKO mice also showed a significant decrease of 
bone marrow stromal cell numbers suggesting a decrease in the stromal niche size (Zhao et 
al., 2012), suggesting that the noncanonical NF-!B signalling pathway can regulate 
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interactions of HSCs with their microenvironment.  However, the detailed role of individual 
members of this transcription factor family in murine HSCs has not been described before.   
The aim of the work described in this thesis was to clarify which NF-!B family genes are 
significant for HSC function.  Expression of NF-!B genes was initially examined using PCR, 
and revealed a clear expression of NF-!B1, NF-!B2, RelA and c-Rel, whereas RelB could 
only be detected after a high number of PCR amplification cycles.  For that reason we decided 
to assess the function of NF-!B1 and NF-!B2 in murine HSCs in vitro and in vivo using 
single gene knockout mice.  
The HSC properties that were tested in cells derived from NF-!B1 and NF-!B2 knockout 
mice included quiescence, proliferation and differentiation capacity.  As part of the study of 
HSC properties, serial transplantation assays were performed into lethally irradiated mice that 
are the only precise way to test HSC potential.  From our study we concluded that NF-!B1 
and NF-!B2 behave differently in term of their in vivo self-renewal capacity.  The fact that 
half of the recipients transplanted with nf!b1-/- KSL cells were engrafted as effectively as 
those transplanted with wild type cells, and that secondary transplantations of these engrafted 
animals were equally successful implies that nf!b1 knockout cells can self-renew to a similar 
extent to the wild type cells.  In comparison, nf!b2-/- KSL transplantations showed a more 
severe phenotype, KSL cells from the same knockout donor mouse either did not engraft 
efficiently or engrafted and exhibited an over-proliferation phenotype and competitive 
advantage with defects in lymphoid and myeloid development.  This implies that NF-!B2 has 
an important function in HSC self-renewal and that its loss affects proliferation control, 
possibly leading to in vivo stem cell exhaustion. However as mentioned already in section 4.8 
it need to be further tested if these cells are undergoing a autonomous or a non-autonomous 
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defect. It is well known that transplation assays are the most precise way to assess stem cell 
function and also the self-renewal capacity of HSCs. But the disadvantage of these 
experiments are that they are very long-term, time consuming and also expensive, as you have 
to keep the mice for more than a year especially if you are performing serial transplantation. 
A cheaper and short term way to gain some idea about self-renewal capacity of HSCs in vivo, 
would be to treat the mice with 5-FU (Fluorouracil). However this would not be as precise as 
transplantation assays. 
Similar to this effect of the absence of NF-!B2 activity, the knockout of a number of genes 
involved in HSC regulation has been shown to have an effect on stem cell self-renewal 
leading to depletion of the stem cell pool when assayed in vivo.  For example, constitutive 
loss of the genes encoding RUNX1, Bmi1, PTEN and Skp2 was demonstrated to cause stem 
cell exhaustion upon transplantation into lethally irradiated mice (Wang et al., 2011, Jacob et 
al., 2010, Park et al., 2003, Yilmaz et al., 2006).  Hence, Bmi1-/- foetal liver and bone marrow 
cells were only able to contribute transiently to haemopoeisis upon transplantation and had 
lost their self-renewal capacity (Park et al., 2003).  A key transcription factor in the 
maintenance of normal HSC function that is being studied in our laboratory, namely c-Myb, 
appears to have a similar controlling effect on self-renewal potential (Garcia et al., 2009).  
Thus, upon transplantation of total bone marrow cells derived from mice with a genetic knock 
down in c-Myb levels, the cells exhibit extensive proliferation.  
Although HSCs from mice lacking NF-!B1 or NF-!B2 behave differently in terms of their in 
vivo self-renewal capacity, in vitro serial replating assays show that the absence of either 
transcription factor can have an effect on self-renewal potential in certain circumstances. 
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The RNA analysis of the NF-!B family members showed that both nf!b1-/- and nf!b2-/- KSL 
cells exhibited an increased level of expression of other NF-!B family members, suggesting 
the possibility for compensation for the loss of the specific factor.  In the case of nf!b1-/- KSL 
cells, there was increased expression c-Rel, suggesting that the mild phenotype observed in 
nf!b1-/- KSL cells could be due to compensation through c-Rel.  In comparison, the in vivo 
and in vitro assays performed on nf!b2-/- KSL cells showed that this transcription factor is 
absolutely required, although the RNA analysis showed an increased level of NF!B1 and 
RelA expression.  It has already been demonstrated that there are multiple mechanisms of 
cross-regulation within the NF-!B family, such as the transcriptional feedback between the 
RHD that is responsible for DNA binding and dimerisation and the I!B protein family 
members (Hoffmann et al., 2003).  c-Rel, RelB and I!B$ are known to be NF-!B target genes 
(Grumont et al., 1993, Bren et al., 2001, Scott et al., 1993).  To study the specific roles of p50 
and p65 in NF-!B dependent gene expression, Hoffmann and colleagues generated fibroblast 
cell lines from nf!b1-/-, rela-/- and nf!b1-/-rela-/- embryos.  This showed that p50/p65 (dKO) 
cells exhibit decreased protein levels of c-Rel, RelB and I!B$.  In addition, nf!b1-/- fibroblast 
cells showed enhanced levels of p52, while c-Rel levels were increased in rela-/- cells 
(Hoffmann et al., 2003).  Thus, this study combined with our RNA analysis of nf!b1-/- and 
nf!b2-/- KSL cells, shows that the NF-!B family members can regulate each other, and that 
the loss of one family member can cause changes in the expression of other members.   
One way to study the effect of NF-!B family members in KSL cells, would be to generate 
double knockout mice and to assess the consequences on HSC maintenance and function.  
RelA-/- mice are embryonically lethal due to liver apoptosis, but animals heterozygous for the 
knockout allele are viable.  Our future plan is to study the function of HSCs in nf!b2-/-rela+/-, 
nf!b-/-nf!b2-/- and nf!b1-/-c-rel-/-mice. However this would also be time and cost consuming.  
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For that reason the plans is to knockout different genes within the NF-!B family by sh-RNA 
and assess the effect on proliferation differentiation e.g by performing conlony asseys and 
then from there to cross the mice which the specific knockout genes to investigate their 
importance in in vivo in KSL cells.   In addition, for us to get a better insight in these 
processes a genome-wide gene analysis of changes in gene expression and parallel studies of 
NF-!B family protein binding to chromatin would be a useful, hoping that NF-!B is biding 
genes that are involved in self-renewal, cell cycle and proliferation such as e.g cyclin D1, 
Runx1 or GATA3.. Such analyses will also help in understanding the proliferative phenotype 
and of nf!b2-/- KSL cells upon transplantation, and could give an overview of the expression 
of niche cytokines, chemokines, adhesion molecules, or cell cycle proteins that might be 
responsible for the proliferation phenotype.   
It is well described that NF-!B activation mediates cell proliferation and that several cell 
cycle regulatory genes are NF-!B target genes.  These include cyclin D1 (Guttridge et al., 
1999), E2F (Cheng et al., 2003), Skp2 (Schneider et al., 2006) and p21 (Hinata et al., 2003), 
each of which is a known key regulator of the cell cycle in HSCs.  In particular, NF-!B2-
dependent pathways have been implicated in cell proliferation and tumourigenesis and it is 
known that the p52 subunit is an important regulator of cyclin D1 expression (Guttridge et al., 
1999).  Furthermore, the RelB/p52 complex has been implicated in the control of transcription 
of the skp2 (Schneider et al., 2006) and c-myc (Demicco et al., 2005) genes.  The fact that NF-
!B can regulate the transcription of these cell cycle regulatory genes, confirms its role as a 
regulator of cell survival, angiogenesis, metastasis and proliferation in cancer cells (Kim et 
al., 2006). 
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It is important to note that inhibition of NF-!B in other cell types does not necessarily lead to 
anti-cancer activity.  For example, inhibition of NF-!B in murine skin resulted in an increase 
in cancer activity (Aggarwal, 2004).  Therefore, depending on the environment, NF-!B 
inhibition or activation can have either a pro- or an anti-cancer outcome.  This is important to 
consider at a clinical level, especially when it is being claimed that an NF-!B inhibiting drug 
is suitable as a therapeutic cancer treatment, when the side effects could include increased 
pro-cancer activity.  Recent research has demonstrated that the long term inhibition of NF-!B 
using Bortezomib, which is a drug used to treat multiple myeloma, can cause increased lung 
tumour growth in mice (Karabela et al., 2012).  In the context of the work peformed in this 
thesis, the fact that loss of NF-!B2 activity can have a proliferative effect, at least within 
haemopoietic stem cells, needs to be taken into account when considering NF-!B family 
member inhibition as a possible treatement to target leukaemic stem cells. 
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Figure A1: Immunofluorescence analysis of  bone marrow cells of wild type and 
nf!b1-/- mice.  Bone marrow from wild type (WT) and nf!b1-/- (KO) mice was 
extracted and the red cells were lysed. Two-dimensional dot plots represent cells gated 
on FSC against SSC (live cell gate). Immunofluorescent staining of bone marrow was 
performed using antibodies against the indicated lineage associated surface markers. 
(A) B-cell markers B220 and CD43. (B) T-cell markers CD4 and CD8a. This figure 
represents typical dot plots from 6 analysed  wild type and 6 analysed KO bone 
marrow mice 
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Figure A2: Immunofluorescence analysis of  bone marrow cells of wild type and 
nfkb1-/- mice.  Bone marrow from wild type (WT) and nf!b1-/- (KO) mice was extracted 
and the red cells were lysed. Two-dimensional dot plots represent cells gated on FSC 
against SSC (live cell gate). Immunofluorescent staining of bone marrow was performed 
using antibodies against the indicated lineage associated surface markers. (A) 
Myelomonocytic markers CD11b and Gr1. (B) Progenitor and  megakaryocytic markers 
c-Kit and CD41. (C) Erythroid markers Ter119 and CD71. This figure represents typical 
dot plots from 6 analysed  wild type and 6 analysed KO bone marrow mice 
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Figure A3: Immunofluorescence analysis of  bone marrow cells of wild type and 
nf!b2-/- mice.  Bone marrow from wild type (WT) and nf!b2-/- (KO) mice was 
extracted and the red cells were lysed. Two-dimensional dot plots represent cells gated 
on FSC against SSC (live cell gate). Immunofluorescent staining of bone marrow was 
performed using antibodies against the indicated lineage associated surface markers. 
(A) B-cell markers B220 and CD43. (B) T-cell markers CD4 and CD8a. This figure 
represents typical dot plots from 6 analysed  wild type and 6 analysed KO bone 
marrow mice 
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Figure A4: Immunofluorescence analysis of  bone marrow cells of wild type and 
nf!b2-/- mice.  Bone marrow from wild type (WT) and nf!b2-/- (KO) mice was extracted 
and the red cells were lysed. Two-dimensional dot plots represent cells gated on FSC 
against SSC (live cell gate). Immunofluorescent staining of bone marrow was performed 
using antibodies against the indicated lineage associated surface markers. (A) 
Myelomonocytic markers CD11b and Gr1. (B) Progenitor and  megakaryocytic markers 
c-Kit and CD41. (C) Erythroid markers Ter119 and CD71. This figure represents typical 
dot plots from 6 analysed  wild type and 6 analysed KO bone marrow mice 
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